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ABSTRACT 
 
Therapeutic proteins or biopharmaceuticals have been playing an ever-increasing role 
in the treatment of human diseases over last 40 years. One of the main challenges with 
manufacture of these proteins is the stabilization of both the finished product and its 
processing intermediates during storage. Freezing and frozen storage is widely applied 
to improve stability of the bulk drug substance. The process of freezing a protein 
results in stresses that can cause protein degradation and subsequent aggregation. 
The aim of this project was to evaluate the effect of parameters involved with freezing 
and thawing of a formulated monoclonal antibody solution in polycarbonate bottles 
and to assess the scalability of these experiments to the respective full-scale 
commercial process. 
Initial experiments were performed to characterise the formulation and develop 
analytical methods that can detect change in unfolding and aggregation of a fully 
human IgG1 monoclonal antibody (‘Protein Y’). A designed set of experiments were 
then executed to understand the effect of parameters involved in freezing and thawing 
steps of a formulated therapeutic protein solution on protein aggregation and 
perturbations in tertiary structure. Results showed that the processing parameters 
studied caused significant variation in freeze and thaw process times, with the factors 
causing slower rates of freeze and thaw also shown to cause changes in the tertiary 
structure of Protein Y. Despite the observed changes in tertiary structure, the effect on 
aggregation was less pronounced, with only a significant change noted for the 
polydispersity index (PdI), as measured by dynamic light scattering (DLS).  
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1.0 INTRODUCTION 
1.1 Therapeutic Proteins 
Therapeutic proteins are a subset of biopharmaceuticals which have been playing an 
ever-increasing role in the treatment of human diseases over the last 40 years. These 
protein therapies have made great advances in the treatment and prevention of many 
rare and severe diseases including diabetes, cancer, anaemia, autoimmune and 
inflammatory diseases (Lamanna et al., 2018). 
There are several variant classes of therapeutic protein, including vaccines, hormones, 
enzymes, monoclonal and polyclonal antibodies and fusion proteins. Over 370 
biopharmaceutical drug products using protein molecules were approved to date for 
human therapeutic use in the European Union (EU) and United States of America 
(USA). The most dominant sub-class within therapeutic proteins are monoclonal 
antibodies, which have comprised over half (53%) of first time approvals from 2015 to 
July 2018 (Walsh, 2018). 
However, based on the multi-dimensional nature of these therapeutic proteins relative 
to small molecule therapies, the increased effectiveness in treatment comes with added 
complexity to ensure that protein critical quality attributes (CQAs) are maintained. 
The biological function and activity of these therapeutic proteins are defined by their 
specific three-dimensional structure and shape, which can be broken down into 
primary, secondary, tertiary and sometimes quaternary structure. Protein folding and 
unfolding are crucial ways of regulating biological activity and targeting proteins to 
different cellular locations. Only correctly folded proteins have long-term stability in 
crowded biological environments and the failure of proteins to fold correctly, or to 
remain correctly folded, is the origin of a wide variety of pathological conditions 
(Dobson, 2003). 
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Antibodies are a type of immunoglobulin made by B-cells in the body when the cell 
encounters its matching antigen. B-cells mature in the bone marrow and activation 
occurs in lymphoid tissues. Each mature B-cell makes a specific antibody that 
recognises a specific antigen. Antibodies contain two identical heavy polypeptide 
chains and two identical light polypeptide chains as illustrated in Figure 1-1. 
Furthermore, each chain contains a variable region and a constant region. The variable 
regions of the heavy and light chains come together to form two antigen binding sites 
(the ‘tips’ of the Y), known as the Fab region. The opposite end of the chains form, the 
constant region, which encodes effector functions that destroy whatever is bound by 
the Fab region. The chains are connected together by disulphide bonds and non-
covalent forces (Vermeer and Norde, 2000). 
 
Figure 1-1: Illustration of a monoclonal antibody structure (Shah et al., 2018) 
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1.2 Monoclonal Antibody Manufacturing Process 
The nature of the commercial monoclonal antibody manufacturing process means it 
can take a few months to manufacture one batch of formulated drug substance solution 
(FDS). The host cells undergo weeks of scale-up through upstream cell culture 
processes followed by several purification operations. In addition, as the proteins are 
expressed biologically from inside a host cell there is inherent variability linked with 
the expression based on the cell line, between different clones derived from the same 
parental cell line and even between proteins produced by the same cell (Vulto and 
Jaquez, 2017). The process of manufacturing therapeutic proteins expressed from 
mammalian cells typically follows a common process flow with subtle product 
specific variation. 
The first step of the process is to extract cells from a cell bank for initiation of cell 
culturing in growth media. This is usually started in shaker flasks at sub-one litre 
levels. The cell culture is scaled up until a sufficient cell density is reached to perform 
harvest of the expressed protein. Clarification is then performed to remove cell debris 
from the solution. This is typically done by depth filtration or centrifugation. The 
protein solution is then purified via a number of chromatography steps. Removal of 
viruses occurs through filtration. The protein solution is concentrated to the correct 
content via ultrafiltration and diafiltration, followed by further filtration to ensure 
sterility and formulation to ensure drug product stability. The formulated drug 
substance solution is then aseptically filled into the primary container closure system 
for dosing to patients. The container closure system can be a vial, pre-filled syringe or 
cartridge for insertion into an injector pen. Furthermore, FDS filled into vials may be 
lyophilised (freeze-dried) to ensure drug product stability is maintained (Jagschies et 
al., 2018). 
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With the rapid growth of the biologic drug pipeline, new challenges have arisen with 
regards to formulating and processing of such products. One of the main challenges is 
the stabilization of biologics, both as a finished product, as well as processing 
intermediates during storage. Besides lyophilisation, a well-established process often 
used for finished products (i.e. FDS) is freezing. Frozen storage is widely applied to 
improve stability of bulk drug substance or clinical trial formulations. In addition to 
increased quiescent storage stability, both lyophilized and frozen products are less 
sensitive to mechanical stress experienced during transport (Radmanovic et al., 2013). 
In the case of liquid formulations, mechanical stress during transport (e.g. shaking) 
results in significant changes to protein critical quality attributes, necessitating 
extensive transport studies. A further advantage of frozen storage is a significant 
reduction of microbial growth, which is especially relevant in the case of bulk drug 
substance storage. All these considerations result in a significant interest in frozen 
storage of biologic products.  
 
1.3 Destabilisation and Aggregation of Therapeutic Proteins 
Degradation of protein refers to a physical or chemical change from the native 
conformation that may result in inactivity and/or aggregation. Degradation is usually a 
prelude to aggregation, where aggregation refers to the association of two or more 
protein molecules. Protein aggregates can cause immune responses resulting in 
adverse effects in patients ranging from skin rashes to anaphylaxis (Wang and 
Roberts, 2010). Therefore, it is critical to understand these mechanisms of aggregation 
and therefore prevent them occurring prior to patient administration. 
There are a number of external factors to which protein molecules are subjected during 
manufacturing that could induce degradation. Aggregation and related particle 
formation is a dominant degradation pathway of antibodies and can occur during all 
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stages of protein therapeutic processing and storage (Singh and Nema, 2010). 
Antibody aggregation is complex and can proceed through covalent or non-covalent 
association that is highly dependent on the solution conditions, including pH, ionic 
strength, and excipients. The covalent associations can be due to disulphide or non-
disulphide covalent bonds, while the non-covalent associations usually appear as a 
result of hydrophobic or electrostatic interactions (Singh and Nema, 2010).      
Figure 1-2 describes different protein aggregation pathways and shows that pathways 
can lead to reversible and non-reversible aggregation. Covalent aggregates are 
generally irreversible and occur as the result of a chemical modification such as 
oxidation. Reversible aggregation can include the association of the hydrophobic 
patches of two proteins that are partially unfolded caused by the physical stresses of 
processing. Partially unfolded proteins aggregate easier than fully unfolded proteins 
due to the optimal exposure of hydrophobic patches. As aggregates increase in size 
they precipitate from the solution, becoming visible. Precipitated aggregates or 
flocculation are generally irreversible (Wang et al., 2010). 
 
Figure 1-2: Graphic illustration of major protein aggregation pathways (adopted from Wang et 
al., 2010) 
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Non-native protein aggregation (hereafter referred to as “aggregation”) describes the 
assembly from initially native, folded protein aggregates containing non-native 
intermolecular-sheet structures (Dong et al., 1995). Protein aggregation behaviour, 
such as onset, aggregation rate, and the final morphology of the aggregated state (i.e. 
amorphous precipitates or fibrils) has been found to depend strongly on the properties 
of a protein’s solution environment, such as temperature, pH, salt type, salt 
concentration, co-solutes, preservatives and surfactants, as well as the relative intrinsic 
thermodynamic stability of the native state (Chang, 1996).  
 
1.4 Analytical Techniques to Determine Protein Degradation  
There are several analytical methods that are widely reported to assess levels of 
protein aggregation and structural changes. Size exclusion chromatography (SEC) is a 
well reported technique for detection of aggregation. Also, there are a number of 
techniques for measurement of sub-visible particles, such as dynamic light scattering 
(DLS), micro flow imaging (MFI) and resonant mass measurement (RMM). Changes 
in tertiary structure of the protein may be evaluated using a number of several 
spectrographic techniques such as circular-dichroism (CD), UV-absorbance, 
fluorescence and Fourier-transform infrared spectroscopy (FT-IR). Evaluation of 
thermal events, such as determination of the glass transition and detection of 
denaturation/unfolding of the protein can be studied using differential scanning 
calorimetry (DSC) (Houde and Berkowitz, 2014).  These techniques are discussed in 
more detail in Section 2.3. 
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1.5 Freeze/Thaw-Induced Protein Aggregation 
Freeze–thaw processes can cause aggregation of proteins due to protein structural 
perturbations. In turn, aggregates of therapeutic proteins may elicit undesirable 
immune responses, such as the generation of antidrug antibodies. The mechanisms of 
freeze/thaw-induced protein aggregation are not well understood, in part, because of 
the limitations of many commonly used spectroscopic techniques for the analysis of 
protein structure within frozen samples (Lu et al., 2014). 
Freeze–thawing and increased temperature are two relevant stress factors to which 
therapeutic proteins are exposed during different processing stages including frozen or 
liquid storage, freeze–drying or shipping. For monoclonal antibodies, heat induced 
unfolding can be manifested in several transitions corresponding to the unfolding of 
the Fc and the Fab parts of the immunoglobulin (Fesinmeyer et al., 2009; Vermeer and 
Norde, 2000). Heat induced denaturation of IgG generally leads to irreversible 
conformational changes, because of instantaneous aggregation accompanying the 
unfolding process (Vermeer and Norde, 2000). Partially unfolded intermediates 
exposing hydrophobic parts, which are often referred to as molten globular 
intermediates, can serve as nuclei for aggregate formation (Dill and Shortie, 1991; 
Fesinmeyer et al., 2009). 
Freeze–thawing combines several stress factors for a protein, all of which can lead to 
aggregation (Bhatnagar et al., 2007). During freezing a protein can adsorb to the ice–
liquid interface or to the container surface inducing a partial unfolding of the protein 
and subsequent aggregation (Chang, 1996; Sarciaux et al., 1999; Strambini and 
Gabellieri, 1996). In addition to formulation and container material related factors, 
process conditions like freezing and thawing rates play an important role for the 
stability of a protein upon freeze–thawing (Cao et al., 2003; Kueltzo et al., 2008). 
These studies referenced focused mainly on the impact of external factors such as 
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excipients, primary packaging material or freezing rates on the extent of protein 
aggregation after freeze–thawing, rather than on the structural properties of the formed 
aggregates. 
Freezing-induced denaturation of proteins is a major concern in the development of 
protein pharmaceuticals. Bulk or final protein products are stored for extended periods 
in the frozen state, which can protect against undesirable chemical degradation. 
Freezing also plays a crucial role in the damage incurred to proteins during freeze-
drying. Freeze-induced denaturation can be inhibited by including protein-stabilizing 
solutes in the formulation. Despite the numerous freeze-thawing studies on proteins 
(Hawe et al., 2009; Kueltzo et al., 2008; Radmanovic et al., 2013; Rayfield et al., 
2016), the choice of these solutes and development of stable formulations is still 
largely empirical because of the lack of a full understanding of the relative importance 
of the various stresses arising during freezing as well as the mechanisms by which 
additives protect proteins against these stresses. Routinely recognized freezing-
induced stresses include cold temperature, exposure to concentrated solutes due to 
crystallization of both water and solutes, and the resultant pH changes if buffer salts 
are involved. Resistance to all of these stresses can be increased if selected solution 
conditions can increase the thermodynamic stability of the native state of the protein 
(Chang, 1996). Freezing-induced stress factors are further discussed in the following 
sub-sections. 
1.5.1 Cryo-Concentration 
During the process of freezing, water is removed from the amorphous phase as ice 
formation occurs and is more likely to occur with slower freezing rates. The slower 
freezing rate results in a smaller number of larger ice crystals that have a lower surface 
area of ice and thus provide a greater opportunity for the protein molecules to coalesce 
and interact with each other. This phenomenon which occurs during the freezing is 
9 
 
known as cryo-concentration and can lead to an increase in buffer and protein 
concentration. Increased protein concentration can result in a higher degree of 
aggregation due to increased opportunity of molecular collisions between protein 
molecules (Kueltzo et al., 2008). 
In addition to changes in the formulation pH, concentration of the protein and 
excipients, the freezing step can also lead to the formation of water-ice interfaces. At 
these interfaces protein adsorption can induce partial protein unfolding and subsequent 
aggregation. A fast-freezing rate will typically lead to formation of smaller ice crystals 
and thus, a larger liquid-ice interface. Chang studied the hypothesis that denaturation 
during freeze-thawing is greater when proteins are frozen with conditions that should 
generate an increased ice surface area (Chang, 1996). The results of previously 
reported studies did not unequivocally support the hypothesis that the ice-water 
interface is the source of this damage because other complex physicochemical changes 
occurring during the freeze-thawing processes were not fully controlled (e.g. 
alterations in pH due to selective buffer salt crystallization and lowest temperature of 
exposure) (Hsu et al., 1995; Nema and Avis, 1993). The results of Chang’s study 
showed that a very slow cooling rate resulted in a much lower ice surface area than 
that for quench freezing (immersing the sample container in liquid nitrogen). The 
greater ice surface area generated by quench cooling provided much more stress to the 
protein than slow cooling, suggesting that denaturation at the surface plays an 
important role in the aggregation of proteins during freezing (Chang, 1996). 
Studies on individual proteins have reported that denaturation during freeze-thawing is 
greater when proteins are frozen under conditions that should generate a relatively 
large ice surface area than when conditions leading to less surface area are employed 
(Chang, 1996; Hsu et al., 1995). One example is a study by Strambini and Gaballieri 
who found that an increase in ice surface area correlated directly with increased 
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perturbation of the tertiary structures of azurin, alkaline phosphatase and liver alcohol 
dehydrogenase in the frozen state, while other physicochemical changes were kept 
equivalent (Strambini and Gabellieri, 1996).   
The concentration profile of solutes entrapped between the ice crystals results from a 
balance between the ice front velocity versus the rates of diffusive and convective 
transport of solute away from the interface. Solute exclusion from the nucleating ice 
domains is influenced by differences in interfacial energy as well as the crystal lattice 
structure, whereas solute inclusion results when the ice growth rate exceeds the solute 
mass transfer rate away from the advancing ice front (Miller et al., 2013).  
Chang also showed that low concentrations of surfactants (i.e. below the critical 
micellar concentration), which would not be expected to greatly alter the free energy 
of protein denaturation, provide a high degree of protein protection during freeze-
thawing (Chang, 1996). Surfactants are known to stabilize proteins against surface-
induced denaturation, so the results suggested that the ice-water interface can 
contribute to freeze-induced protein denaturation (Chang, 1996).  
1.5.2 Solute Crystallisation 
Selective crystallisation of buffer components can occur depending on the cooling rate 
applied for freezing or the buffering effect of the salts used in the formulation (e.g. 
crystallisation of disodium phosphate prior to that of monosodium phosphate, which 
results in a decrease in pH) (Chang, 1996). Each buffer salt has its own critical cooling 
rate. Crystallisation will only occur when the cooling rate is slower than the critical 
cooling rate. Therefore, if a protein solution is quench cooled with liquid nitrogen, it is 
likely that buffer salts will remain amorphous. In contrast, crystallisation and a 
subsequent change of pH can readily occur during slower cooling (Chang, 1996). This 
was also observed for other excipients. Izutsu et al. demonstrated that mannitol 
crystallisation reduced its cryo-protectant effect, resulting in a reduction in activity of 
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a model enzyme (β-galactosidase), whether it was freeze-dried or freeze-thawed 
(Izutsu et al., 1993). Sorbitol has also the potential to crystallise in the frozen solution 
and has been shown to cause increased levels of aggregation in a fusion protein 
(Kantor et al., 2011). 
1.5.3 Low Temperature Destabilisation 
It is well documented that proteins unfold with an increase in temperature (i.e. heat 
denaturation). However, low temperature can initiate cold denaturation of proteins, 
due to an increased solubility of hydrophobic residues at low temperature, favouring 
unfolding (Privalov, 1990). Cold denaturation is a thermodynamic consequence of the 
large heat capacity of unfolding and can be dependent on the pH of the solution, 
concentration of the protein and presence of additives such as sugars and chaotropic 
agents (Bhatnagar et al., 2007). Moreover, during freezing a protein can adsorb to the 
ice–liquid interface or to the container surface inducing a partial unfolding of the 
protein and subsequent aggregation (Strambini and Gonnelli, 2007).  
1.5.4 pH Shifts 
Exposure of monoclonal antibodies to an acidic environment can result in 
conformational changes and aggregation (Jiskoot et al., 1991). As described above, 
particularly for sodium phosphate buffers, cooling and freezing can result in selective 
crystallisation of different buffer components, potentially resulting in pH shifts of the 
frozen solution. The pH shifts have been reported to decrease pH to pH 4.0 for sodium 
phosphate buffers (Pikal-Cleland et al., 2000; Gómez et al., 2001) and to pH 3.0 for 
succinate buffers (Lam et al., 1996) . 
The degree of reduction in pH of sodium phosphate buffered solutions during freeze-
thawing depends on the degree of dibasic salt crystallisation, which in turn is dictated 
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by processing parameters. As a result of this, it is generally recommended to avoid use 
of sodium phosphate buffers for bulk drug substance (Wang and Roberts, 2010).  
1.5.5 Exposure to Liquid-Air Interface 
Agitation can sometimes be utilised to speed up the thawing process, particularly for 
uncontrolled thawing processes. Mechanical stresses may cause shear or interfacial 
effects in which the protein adsorbs to the air-water interface, leading to structural 
alterations which can initiate aggregation. Both stirring and shaking are mechanical 
stresses that can also cause cavitation, local thermal effects, bubble entrapment, and 
transportation of the aggregated protein from the air-water or air-container interface 
into the bulk solution (Telikepalli et al., 2014). 
1.5.6 Polar Interactions  
A common feature of monoclonal antibodies is that non-polar regions are sequestered 
into the core of the protein, where they avoid contact with water (Vermeer and Norde, 
2000). Privalov showed that the cold denaturation is a general phenomenon caused by 
the very specific and strongly temperature-dependent interaction of protein nonpolar 
groups with water (Privalov, 1990). Hydration of these groups is favourable 
thermodynamically, i.e. the Gibbs energy of hydration is negative and increases in 
magnitude at a temperature decrease. As a result, the polypeptide chain, tightly packed 
in a compact native structure, unfolds at a sufficiently low temperature, exposing 
internal nonpolar groups to water (Privalov, 1990). 
Polar interactions between water molecules and the hydrophilic patches of proteins 
help maintain the native conformation, hence the dehydration of a protein can promote 
unfolding. Inevitably this leads to increases in aggregation levels due to protein-
protein interactions. The mechanism involves a decrease in charge density due to the 
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transferring of protons to carboxyl groups during dehydration (Rupley and Careri, 
1991). 
1.6 Freeze/Thaw Studies of Therapeutic Proteins   
A major focus of published freeze-thaw studies for therapeutic proteins is the effect of 
controlled versus uncontrolled systems. Rayfield et al. described an uncontrolled 
system as one in which a filled drug substance container is placed into a temperature 
control unit until the material is frozen. Similarly, for uncontrolled thawing, the frozen 
drug substance container is placed into ambient conditions until fully liquefied 
(Rayfield et al., 2016). Although, as some proteins may be more susceptible to 
aggregation from the stresses imposed during phase changes from liquid to solid and 
back again, a more controlled system to provide for heat transfer from and to the 
solution may be advantageous to protect the protein from damage. In addition, a 
controlled system may offer quicker cycle times for freeze and thaw of proteins, 
allowing shortened overall process time for storage and filling of the formulated 
protein solutions (Rayfield et al., 2016). 
CryoVesselTM (Integrated Biosystems, Inc.) and Celsius® CFT Technology (Sartorius-
Stedim Biotech.) are two examples of controlled systems currently commercially 
available. A large scale cryo-vessel (e.g. CryoFinTM) is a portable, jacketed, stainless 
steel freeze-thaw vessel used for cryopreservation of biopharmaceuticals, vaccines, 
blood products and gene therapy products, offered in volumes ranging from 20 to 500 
L. Volume compartmentalization results in reduction of freezing path lengths, creation 
of extended heat transfer surfaces to increase heat flux and control of freezing rate. 
This represents a compact, dimensionally optimized containment design. 
CryoWedgeTM is a scaled down model of the cryo-vessel that can be used to assess the 
impact of the freeze-thaw cycle on the product quality (Padala  et al., 2010). Celsius® 
CFT is a controlled rate freeze-thaw system offering a full line of disposable single-
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use bags (Celsius®-Pak’s varying in volume from 30 mL to 16.6 L), control units, 
freeze-thaw modules, transfer carts, storage modules, and shipping units. Celsius® 
systems are optimally scalable. The Celsius® S3 Freeze-Thaw Module, the bench-top 
system, is specifically designed for development and stability studies and allows 
freeze-thaw runs with as little as 30 mL of product under the same conditions as the 
production scale system. The FT16 Celsius® system, with a capacity of up to 16 L, 
offers a pilot-scale alternative and can easily be scaled up to the manufacturing scale 
FT 100 Celsius® system, with a production capacity of up to 100 L (Padala et al., 
2010). The ability to provide a linear scale-down model using the Celsius® S3 system 
has also been studied by Rayfield et al. and shown to provide a linear scale-down 
comparison of the manufacturing process where analytical data is comparable between 
small and large scales (Rayfield et al., 2016). 
Another controlled system designed by HOF Sonderanlagenbau GmbH also utilises 
single-use bags. In contrast, to the Celsius® systems, bags are frozen in a horizontal 
position with heat-flow being controlled to the faces of the bag rather than to the 
edges. This utilises a larger surface area for freeze-thaw and thus, potentially quicker 
process throughput. However, to the best of our knowledge there are no scientific 
studies reported at this point demonstrating the benefits of this system. 
Freezing and thawing processes may also detrimentally affect product quality 
requiring detailed process understanding and proper process control. Initially, research 
into freezing–thawing of pharmaceutical products focused on establishing the effect of 
formulation composition on product quality after freeze–thawing and frozen storage. 
So far, only a few authors have studied the effect of freezing–thawing process 
conditions on product quality (Radmanovic et al., 2013; Rayfield et al., 2016). 
Quick freezing of enzymes in liquid nitrogen was often recommended in order to 
preserve the enzymatic activity (Nema and Avis, 1993; Shikama and Yamazaki, 
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1961), but Eckhardt et al. reported that rapid freezing in liquid nitrogen failed to 
prevent some proteins from freezing denaturation (Eckhardt et al., 1991). Other studies 
investigating freezing of protein solutions (Chang, 1996; Jiang and Nail, 1998; 
Strambini and Gabellieri, 1996) showed that fast freezing produced more damage to 
proteins and resulted in lower recovery of activity after freezing and thawing. This 
phenomenon was explained as ice-induced partial unfolding of proteins. However, 
despite these studies there is a lack of a systematic study of the freezing rate 
dependence of protein denaturation. Also, there is very little work addressing how 
damage to proteins can be reduced during freezing and thawing, through the 
optimization of operation conditions (Cao et al., 2003). 
 
1.6.1 Scalability 
Scale-down models are important as they can support process development studies 
representing the proposed large scale or commercial process. Moreover, it is a 
regulatory requirement to have a qualified scale-down model. Scale-down models are 
used to understand the process, while alleviating material requirements as well as the 
complication and expense of generating the data on a large-scale system. The 
International Conference on Harmonisation guidance for development and 
manufacture of drug substances (ICH Q11) states that a scientifically justified model 
can enable a prediction of quality and can be used to extrapolate operating conditions 
across multiple scales and equipment (Guideline ICH Q11, 2012). 
Freeze-thaw rates can be challenging to duplicate on scaling. Large-scale heat transfer 
is slower and less efficient. As tank volumes get larger, the surface area to volume 
ratio decreases rapidly. Therefore, to affect temperature changes as rapidly as at small 
scale the temperature required at the surface of tanks and heat exchangers must be 
higher and mixing must be better (Wang and Roberts, 2010). Slow freezing and 
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thawing increase the exposure of the protein to localised zones of high protein 
concentrations, high solute concentrations and increased ice-liquid surface exposure.  
The important parameters to be considered for the drug substance container are the 
heat transfer rate and freeze path length. These parameters are difficult to model in an 
uncontrolled freeze process. The first parameter, heat transfer, can be dependent on 
environmental factors within the temperature control unit, which in turn is dependent 
on air flow and unit capacity. The second parameter, freezing path length (the distance 
from the container surface to the last point to freeze), is often not consistent between 
scales (Rayfield et al., 2016). 
To evaluate small scale models (≤1 L) Rayfield et al. sought a correlation between two 
factors; surface area to volume ratio (SA:V) and freeze time. A SA:V ratio is related to 
the freeze path length which impacts the resulting freeze time. Containers with higher 
SA:V ratio have shorter freeze path lengths and will therefore freeze and thaw faster. 
To evaluate the impact of SA:V ratio, freezing and thawing was performed on a 
monoclonal antibody using containers in multiple sizes and both the controlled and 
uncontrolled rate of freezing and thawing parameters. The findings showed that a scale 
down model for 30 ml was sufficient to provide a linear comparison to the 
manufacturing scale process for stable molecules  (Rayfield et al., 2016).  
A general strategy for scale-down model development is to proportionally scale down 
the volume-dependent parameters (freeze time, SA:V ratio) while maintaining the 
volume-independent parameters (heat transfer, fluid temperature, material of 
construction) at the same set points used in the large-scale (≥ 2 L) process. The scale-
down model is considered applicable as long as the freeze profile is comparable with 
the at scale model for stable molecules (Rayfield et al., 2016). 
Rayfield et al. evaluated the impact of the several parameters on the drug substance 
product quality including freeze/thaw rate, mode of freezing, drug substance container, 
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drug substance concentration and formulation. This was performed by creating 
controlled freeze-thaw programs using a Celsius® S3 apparatus. Freezers were used to 
create uncontrolled freezing rate. Uncontrolled thawing cycles were created by placing 
frozen containers upright on the bench top at ambient temperatures until temperature 
at last point to freeze (LPF) reached 20 °C. Further uncontrolled studies were 
completed, using Celsius S3 programs to mimic an uncontrolled rate large scale-
freezing and thawing within a large scale container and also to mimic shipping 
excursion studies and potential temperature excursions through the glass transition 
(Tg’, typically around -30 °C) that could be experienced during shipping (Rayfield et 
al., 2016).  
Radmanovic et al. investigated a physico-mathematical model to predict product 
temperature profiles based on the freezing program as input parameter in a commercial 
freeze–thaw module. Applying this model, the time from first nucleation until the LPF 
reaching −5 ◦C and the time from −5 ◦C to −30 ◦C at LPF was varied to study the effect 
on product quality attributes in a full factorial design. Effects of process parameter 
settings on a typical fully formulated, highly concentrated monoclonal antibody 
solution as well as a highly concentrated solution formulated with buffer only were 
investigated.  A complex dependency of product quality attributes was observed on 
both freezing and cooling time and it was found that fully formulated drug product 
was significantly less susceptible to freeze–thaw stress than a drug substance 
formulation containing histidine buffer only (Radmanovic et al., 2013). 
Studies can also be performed at a very small scale, which allows for faster 
experimentation but would not be expected to simulate an industrial process. Hawe et 
al. froze IgG samples at scale of 1.5 ml contained within reaction tubes and identified 
suitable stress conditions with respect to heating temperature and time, as well as the 
number of freeze–thawing cycles. The aim was to obtain representative samples for 
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both types of stress, containing low but measurable levels of aggregates. 
Characterisation techniques including UV spectroscopy, DLS, light obscuration and 
HP-SEC revealed that similar types of aggregates were formed when varying the 
heating time between 1 and 20 minutes and the heating temperature between 70 and 75 
°C, or the number of freeze–thawing cycles between one and five. Differences were 
mainly found in the amount of aggregation. Based on this, heating for 10 minutes at 74 
°C and five repetitive freeze–thawing cycles were suggested to create representative 
samples for further physico-chemical characterisation (Hawe et al., 2009). 
An important consideration for any study is the requirement to prove that undergoing 
freeze/thaw cycling does not impact the stability of the therapeutic protein. Rayfield et 
al. placed samples on an accelerated stability program at 40 °C for 4 weeks and found 
no effect on product quality attributes (no increase in particles or change in variants, or 
oxidation species) relative to control (no freeze/thaw). The freeze/thaw study and the 
stability data generated suggest that rate of freeze and thaw, container type/size, and 
mode of freezing did not impact the product quality during the process or stability over 
time for the monoclonal antibody studied. However, it should be noted that the studied 
therapeutic molecule was also relatively stable on account of a well-designed molecule 
sequence supporting its stability (Rayfield et al., 2016). 
Although several studies have been performed to evaluate the impact of freezing on 
protein quality, these studies are limited to small volumes, where the effect of 
processing parameters such as freezing/thawing rate cannot be correlated to large scale 
systems. Due to freezing of protein solutions, series of phenomena noted above (pH 
changes, cryo-concentration, ice–water interface denaturation, etc.) are predominantly 
dependent on the freezing/thawing rate, freezing temperature, freezing time, and most 
importantly the overall ‘‘solution working volume’’. Additionally, when the scale is 
small (small heat and mass transfer dimensions), it is difficult to study the impact of 
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cryo-concentration, solute redistribution and time in transition phase effects and 
correlate the observed results to large scale. Therefore, there is a need to perform such 
experiments at manufacturing scale. Understanding of these effects is essential to 
better define the process parameters during large scale freezing/thawing and hence, to 
minimize the impact on protein quality (Kolhe and Badkar, 2011). 
 
1.7 Aims and Objectives  
Based on the literature review described above, the overall aim of this thesis was to 
evaluate the effect of parameters involved in freezing and thawing steps on freezing 
and thawing time, cryo-concentration, and the aggregation and tertiary structure of a 
formulated therapeutic protein solution, stored in polycarbonate bottles at a small-
scale (lower than commercial volumes). The work was also envisaged to assess the 
scalability of these experiments to the respective full-scale commercial process.  
To achieve these aims, the following specific objectives were established for the 
project; 
 Establish a set of analytical methods to characterise the therapeutic protein focusing 
particularly on its aggregation and tertiary structure. 
 Execute a designed set of experiments to evaluate the key factors; (1) that could 
cause change in protein structure, (2) that could cause change in aggregate levels in 
the formulated drug substance and (3) predict the influence of parameters on 
freezing and thawing times. 
 Evaluate the validity of a small-scale model and understand the behaviour of the 
respective full-scale commercial process. 
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2.0 EQUIPMENT, MATERIALS AND METHODS 
2.1 Equipment 
The list of the equipment used for the experimental work is presented in Table 2-1. 
Table 2-1: List of the equipment used 
Equipment Type Manufacturer Country 
SSM1 Mini orbital shaker Stuart United Kingdom 
Lexicon II ULT freezer (set to -80 °C) ESCO Singapore 
 Mediline freezer (set to -20 °C) Leibherr Germany 
OMT lab oven (set to 45 °C) Sanyo Japan 
Tracksense Pro X Temperature Probes ELLAB Denmark 
Zetasizer µV Malvern United Kingdom 
FT-4 Fluoromax fluorescence 
spectrometer 
Horiba Scientific Japan 
Chirascan cicular dichroism 
spectrometer 
Applied Photophysics UK 
Q2000 DSC TA Instruments USA 
SEC HPLC system Waters USA 
SevenEasy pH Meter Metteler Toledo USA 
Haake Mars Rheometer Thermo Fisher USA 
 
2.2 Materials 
Table 2-2 summarizes all materials and reagents used in this study.  
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Table 2-2: List of the materials used 
Material Grade Supplier Application 
Protein Y N/A Sanofi Active pharmaceutical 
ingredient 
Histidine USP / Ph Eur Sigma Dilution buffer 
preparation 
Histidine, mono-
hydrochloride, 
monohydrate 
>98 % Sigma Dilution buffer 
preparation 
Sucrose BioUltra 
(>99.5 %) 
Sigma 
Aldrich 
Dilution buffer 
preparation 
Tween 20® 
(Polysorbate 20) 
Molecular 
Biology 
Sigma 
Aldrich 
Dilution buffer 
preparation 
Milli-Q® water HPLC grade Millipore Dilution buffer and 
HPLC mobile phase 
preparation 
Universal Indicator 
solution 
N/A Lennox 
Laboratories 
Monitoring pH change 
Sodium chloride, 5M 
solution 
>99.5%, Ph 
Eur 
Fisher HPLC mobile phase 
Disodium hydrogen 
phosphate heptahydrate 
>98% ACS 
reagent 
Acros 
Organic 
HPLC mobile phase 
Sodium phosphate 
monobasic monohydrate 
>98% ACS 
reagent 
Acros 
Organic 
HPLC mobile phase 
Orthophosphoric acid, 
concentrated 
>85% Fisher HPLC mobile phase 
Sodium hydroxide, 1N 
solution 
N/A Fisher HPLC mobile phase 
Sulphuric acid, 1M N/A Fisher HPLC mobile phase 
Sodium sulphate 
anhydrous. 
N/A Fisher, HPLC mobile phase 
Acetonitrile, HPLC 
grade 
99.9%, HPLC 
gradient grade 
Fisher HPLC mobile phase 
Protein reference 
standard 
In-house Sanofi HPLC analysis 
Gel filtration standard 
(molecular weight std) 
N/A Biorad HPLC analysis 
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2.2.1 Drug Substance Technical Overview 
The active pharmaceutical ingredient (API) of the product, Protein Y, is a fully human 
IgG1 monoclonal antibody. An illustration of the Protein Y molecule is shown in the 
Figure 2-1. The antibody, based on the primary sequence (in the absence of N-linked 
glycosylation), possesses a molecular weight of 145,983.8 Da, taking into account the 
formation of 16 disulphide bonds and removal of Lys448 from each heavy chain C-
terminus (Internal Common Technical Document, Sanofi). 
 
Figure 2-1: Illustration of the molecular structure of Protein Y (Internal Common Technical 
Document, Sanofi) 
 
2.2.2 Bulk Manufacturing of Protein Y 
Protein Y is generated via recombinant DNA technology and expressed in 
manufacturing using Chinese Hamster Ovary (CHO) cells. The process is initiated at 
the seed lab where the CHO cells are inoculated into shake flasks and subsequently 
into a cell bag for expansion of the cultures. The cell numbers are further expanded in 
bioreactors, prior to harvest of the protein through centrifugation and filtration. The 
protein is purified via an intensive series of chromatography, viral inactivation and 
filtration steps. Finally, the bulk is formulated and stored in the frozen state in 
preparation for filling into syringes. 
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2.2.3 Formulation of the Product 
The composition of the formulated drug substance (FDS) is listed in Table 2-3. 
Table 2-3: Nominal composition of Protein Y solution for injection 
Component Function/ 
Characteristic 
Reference to Quality 
Standard 
Protein Y active ingredient In-house specification 
Histidine a, b buffering agent USP, Ph. Eur., JP 
Histidine, Mono-hydrochloride, 
monohydrate b, c 
buffering agent Ph. Eur., JP 
Sucrose tonicity and 
stabilizing agent 
NF, Ph. Eur., JP 
Polysorbate 20 stabilizing agent NF, Ph. Eur., JPE 
Water for injection solvent USP, Ph. Eur. 
a Named L-histidine in JP. 
b The amounts of L-histidine mono-hydrochloride monohydrate and L-histidine in the concentrated 
excipient buffer containing 10mM histidine are 1.027 mg/mL and 0.791 mg/mL, respectively.  It is 
expected that the histidine ratio will be similar in the Protein Y drug product. However, given the 
contribution of the two histidines from the diafiltration buffer, the impact of the Donnan effect and the 
contribution from the sucrose adjustment buffer and dilution buffer, actual amounts of L-histidine 
monohydrochloride monohydrate and L-histidine in the DP cannot be calculated. 
c Named L-histidine hydrochloride hydrate in JP. 
JP = Japanese Pharmacopeia; JPE = Japanese Pharmaceutical Excipients; NF = National Formulary;  
Ph. Eur. = European Pharmacopeia; USP = United States Pharmacopeia. 
 
 
2.3 Methods 
2.3.1 Formulation Characterisation Studies  
Prior to evaluation of the impact of processing parameters, initial characterisation 
experiments were performed to understand the bulk FDS in the context of freezing and 
thawing. In particular, the critical temperatures at which the formulation undergoes 
changes (glass transition, Tg’ and collapse temperature, Tc) were determined. In 
addition, changes in pH of the buffer solution during freeze-thaw experiments was 
also assessed. 
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2.3.1.1 Differential Scanning Calorimetry (DSC) 
Both formulated drug substance (FDS) and the dilution buffer solution (without 
Protein Y) were analysed by modulated DSC, each in three replicate runs. DSC 
analysis were performed by cooling the samples to -70 °C and re-heating to +30 °C at 
a ramp rate of 2 °C/min. The modulation period was 100 seconds with temperature 
amplitude of ±1 °C. TA Instruments Hermetic Tzero pans and lids were used for all 
experiments. Data was processed by using the Universal Analysis Software (version 
4.5A). Tg’ values were measured as midpoint temperature of the thermal event 
observed in the reversing heat flow thermogram. 
2.3.1.2 Freeze Drying Microscopy (FDM) 
In order to determine Tc, three FDM runs were performed (runs I-III). All samples 
were cooled at a freezing rate of 10 °C/min to either -60 °C (run I) or -30 °C (runs II 
and III), followed by the holding time of 10 minutes (runs I and II) or 30 minutes (run 
III) to achieve isothermal equilibration. Then, a vacuum of approximately 6000 Pa was 
applied to initiate sublimation and maintained through the temperature ramp of 1 
°C/min until the full collapse of the material was reached, with pictures captured every 
5 seconds.  
2.3.1.3 Evaluation of pH Change in Dilution Buffer 
Universal Indicator solution was added to samples of the dilution buffer in four plastic 
tubes. The dilution buffer and indicator solutions were placed in storage at -80 °C, -20 
°C, +5 °C (refrigerator) and at a controlled room temperature for 2 days. The samples 
were then visually inspected and compared. In addition, the pH of the non-frozen 
refrigerated and the room temperature solutions was measured using a pH meter.  
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2.3.2 Protein Y Characterisation Studies 
A number of analytical characterisation methods were established and optimised to 
confirm their suitability to assess changes in protein aggregation and its tertiary 
structure.  
2.3.2.1 Differential Scanning Calorimetry (DSC) 
The suitability of the DSC technique was assessed for the three sets of samples: (1) 
dilution buffer, (2) FDS diluted to 15 mg/ml (FDS-15) and (3) FDS with high protein 
concentration of 150 mg/ml (FDS-150). Initially, a sample volume of 20 µl and a 5 
minute equilibration at 25 °C was performed for all samples, followed by heating step 
to 100 °C with a ramp rate of 2 °C/min. The method was further optimized by varying 
the sample volume (10 μl and 20 μl), the starting equilibration temperature (25 °C and 
40 °C) and the end temperature (96 °C and 100 °C), as well as the ramp rate (0.5, 1, 2 
and 10 °C/min). TA Instruments Hermetic Tzero pans and lids were used for all 
experiments. Data was processed by using the Universal Analysis Software (version 
4.5A). 
 2.3.2.2 Size Exclusion Chromatography (SEC) 
The SEC-HPLC method was used to separate and detect high and low molecular 
weight species, which are CQAs for Protein Y. The method employed was similar to a 
previously reported method (Bond et al., 2010), and was validated and is in routine use 
for QC release testing in Sanofi. Therefore, no method development was required for 
FDS used in our study.  The method parameters are proprietary to Sanofi. 
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2.3.2.3 Dynamic Light Scattering (DLS) 
An initial DLS analysis was performed to see if freezing and thawing of Protein Y 
effected protein aggregation. Samples of Protein Y FDS in 1.5 ml Eppendorf tubes 
were placed in a freezer at -80 °C for 24 hours, thawed at 40 °C for 20 minutes and 
then this process repeated twice (i.e. three freeze-thaw cycles). This sample was then 
diluted, and a final concentration range from 0 mg/ml (i.e. dilution buffer solution) to 
150 mg/ml (FDS) was analysed using a default DLS method and a sample viscosity of 
0.88 mPaS. Equivalent dilutions were prepared for a control sample of Protein Y, 
which had not been frozen. The effect of Protein Y FDS concentration on the product 
viscosity was performed at 25 °C using the Haake MARS rheometer. It was 
determined that viscosity was constant at 1.4 mPaS between 0 mg/ml (dilution buffer 
only) and 15 mg/ml but increased above this concentration. Therefore, further DLS 
analysis were performed using a sample viscosity of 1.4 mPaS and protein 
concentration of 15 mg/ml. To determine if the DLS method can detect changes in 
protein aggregation, Protein Y samples were aged in Eppendorf tubes for 15 minutes 
at 40 °C and 80 °C. The samples were then diluted to 15 mg /ml (1:10 dilution) and 
analysed by DLS, both unfiltered and filtered through a 0.45 μm filter to assess any 
effect of filtration. A summary of the DLS method parameters used for analysis is 
presented in Table 2-4. 
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Table 2-4: DLS method parameters 
 
2.3.2.4 Circular Dichroism Spectroscopy (CD)/UV-Absorbance 
CD method development was performed at concentration ranges of 0.15 – 1.5 mg/ml 
using a 1 cm path length quartz cuvette, a step value of 0.3 nm and time of 2 seconds 
per point. UV absorbance was recorded in addition to CD to investigate total protein 
content and tertiary structure through second derivative analysis. A concentration of 
0.75 mg/ml was selected to optimum UV absorbance values, however the CD spectra 
generated were not clear. Therefore, the time per point was increased to 5 seconds and 
the step value increased to 1 nm, which resulted in generation of a clearer spectrum. In 
order to determine if the developed method could detect changes in the tertiary 
structure of Protein Y, the method was run with a temperature ramp, and spectra 
recorded at 20, 40, 60 and 80 °C.  
Based on the ability of near-UV CD scans to detect unfolding of Protein Y, the 
parameters listed in Table 2-5 were selected as optimal for the method. 
  
Parameter Setting 
Sample concentration 15 mg/ml 
Sample viscosity 1.4 mPaS 
Sample volume 1.0 ml 
Cuvette Low volume disposable cuvette 
Pre-filtration 0.45 μm 
Reporting data Z-Average and PdI 
Report average of 3 repeats 
Equilibration temperature 25 °C 
Equilibration time 120 seconds 
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Table 2-5: Near-UV/CD parameters 
Parameter Setting 
Sample Concentration 0.75 mg/ml 
Scan range 315 – 250 nm 
Number of replicates 3 
Step 1 nm 
Time per point 5 seconds 
 
2.3.2.5 Fluorescence Spectroscopy 
Intrinsic fluorescence spectroscopy was employed for analysis of the FDS containing 
Protein Y at protein concentration of 150 mg/ml (undiluted) and subsequent dilutions 
to 0.15 mg/ml, with excitation at 295 nm. The excitation was then adjusted to 280 nm 
in order to maximise the intensity for tryptophan residues. Furthermore, optimum slit 
widths were investigated to determine the best setting that provides a corrected 
intensity ratio of less than 2 x 106 units. A temperature ramp was also performed, 
samples were heated using a water bath at 20 °C, 40 °C, 60 °C, 80 °C and analysed 
after cooling back to 20 °C. Optimized method parameters are detailed in Table 2-6. 
Table 2-6: Fluorescence method parameters 
Parameter Setting 
Sample concentration 0.75 mg/ml 
Sample volume 1 ml 
Cuvette 1 ml Low volume quartz cuvette 
Excitation 280 nm 
Excitation slit 1.5 nm 
Emission scan range 295 – 450 nm 
Emission slit 1.5 nm 
Reporting data Intensity, λmax 
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2.3.3 Freeze-Thaw Studies 
2.3.3.1 Experimental Design of Experiments (DoE) 
Following the initial formulation characterization studies and optimization of the 
analytical characterization methods, a designed set of experiments (DoE) was 
performed to provide an assessment of different freeze/thaw process parameters 
related to the current uncontrolled freeze/thaw steps in the manufacturing process that 
were thought to have the potential to affect the properties of Protein Y. The following 
five parameters were selected and input into the design:  
 Freezing temperature; the temperature inside the freezer used to freeze the FDS 
 Freezing equilibration; the temperature inside the freezer prior to removal from 
the freezer for thawing 
 Freeze co-load; a categorical factor used to mimic the FDS being loaded on its 
own or with other bottles. If co-loaded, the surrounding bottles were filled with 
water (Figure 2-2).  
 Thaw co-load; a categorical factor used to mimic the FDS being thawed on its 
own or with other bottles. If co-loaded, the surrounding bottles were filled with 
water (Figure 2-2). 
 Thaw agitation speed.  
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Figure 2-2: Container layout for Protein Y freeze and thaw DoE. Top and cross-section view 
As this was an initial screening DoE, a reduced 2-level factorial design, with no blocks 
or centre points was selected in order to provide an appropriate level of runs for 
execution, which would allow for single factors having a significant effect to be 
identified. This design resulted in eight runs evaluating the five factors chosen, as 
presented in Table 2-7 and Table 2-8. 
Table 2-7: DoE design for freeze-thaw studies 
Factor Name Units Type 
Low 
Actual
High 
Actual 
Low 
Coded 
High 
Coded
A Freezing temperature °C Numeric -80 -20 -1 1
B Freezing equilibration °C Numeric -80 -20 -1 1
C Freeze co-load n/a Categoric Yes No n/a 
D Thaw co-load n/a Categoric Yes No n/a 
E Thaw agitation speed rpm Numeric 0 69 -1 1
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The DoE design, with the experimental plan listed in Table 2-9 was scheduled and 
freeze-thaw cycles executed over the course of approximately 6-weeks, with 
subsequent 4-week stability profile following the respective runs. Each run consisted 
of one 125 ml bottle containing 87.5 g of FDS. 
Table 2-8: Experimental plan 
Run 
Order 
Freezing 
Temperature (°C) 
Freezing 
Equilibration (°C) 
Freezing 
Co-load 
Thawing 
Co-load 
Agitation 
Speed (m/s) 
1 -20 -20 No No 0.054 
2 -80 -20 No Yes 0 
3 -80 -20 Yes Yes 0.054 
4 -20 -20 Yes No 0 
5 -80 -80 Yes No 0.054 
6 -20 -80 No Yes 0.054 
7 -20 -80 Yes Yes 0 
8 -80 -80 No No 0 
 
Design Expert (V7.02) software was used to perform statistical analysis of the DoE 
results. The responses listed in Table 2-9 were evaluated following each run at time 
zero and after 1, 2 and 4-weeks storage at 45 °C by monitoring the temperature and 
time. Responses related to protein structure were measured by wide range of analytical 
techniques (i.e. UV absorbance, fluorescence spectroscopy, DSC, DLS, SEC-HPLC). 
The DSC was performed at the first and last time-point. In addition to statistical 
responses in the DoE, qualitative assessments were made by comparison of near-UV 
CD, 1st/2nd derivative of UV absorbance and intrinsic fluorescence spectra responses 
from the DoE runs compared to the control sample (i.e. initially thawed bulk FDS).  
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Table 2-9: DoE process responses 
Response Product /process attribute Parameter monitored/analyzed 
Freezing 
process 
performance
Pre-cooling rate (pre-plateau) Temperature over time 
Freezing time (freezing plateau) Time  
Post-cooling rate (post-plateau) Temperature over time 
Overall freezing time (to freezer 
temperature) 
Time 
Thawing 
process 
performance
Initial thaw rate (pre-plateau) Temperature over time 
Thawing time (thawing plateau) Time  
Thaw rate (post-plateau) Temperature over time 
Overall thawing time (to freezer 
temperature) 
Time 
Protein Y 
stability 
Cryo-concentration % RSD of UV absorbance at 280 nm 
(A280)  
Protein Y tertiary structure Arbitrary peak height ratios attributed 
to aromatic amino acid residues in 
second derivative of UV absorbance 
spectra  
Emission intensity and wavelength 
maxima (λmax) of intrinsic fluorescence 
spectra 
Protein Y thermal stability Unfolding temperature onset and mid-
point by DSC 
Protein Y aggregation Z-average and PDI by DLS 
High molecular weight / low molecular 
weight species by SEC HPLC 
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2.3.3.2 Thawing of Bulk FDS  
One 5 L bottle of FDS was removed from frozen storage and thawed by placing the 
bottle on the rotary shaker at room temperature until a liquid layer was visible (approx. 
6 hours). The FDS was then agitated at 69 rpm until thawing was complete 
(approximately 19 hours). Sample aliquots for analysis were taken as per the 
experimental plan. Approximately 87.5 g of FDS was dispensed into each 125 ml 
bottle required for experimentation on the day of initiating the respective freeze/thaw 
experiments. The thawed FDS in the bulk 5 L bottle was stored at 2 – 8 °C during 
execution of the series of experiments. 
2.3.3.3 Freeze/Thawing Experimental Procedure 
Temperature was monitored using the ELLAB probes, which were inserted into the 
125 ml bottles in two locations: inside the bottle with tip of probe suspended near to 
the centre (Probe 1), and on inside wall of the bottle with tip of probe ending at the 
base of the bottle (Probe 2). PTFE tape was used as required to ensure probes remain 
in place (Figure 2-3).  
 
Figure 2-3: Illustration of FDS bottle and ELLAB probe set up 
0.0875 kg Probe 1
Probe 2
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The bottles were placed into the respective freezer as per the DoE plan outlined in 
Table 2-8 and stored for approximately 24 hours to ensure the bottle has equilibrated 
at the freezer temperature. The bottles were then moved to a different freezer if the 
experimental plan required and kept in the equilibration freezer for a further 24 hours. 
Following the bottles removal from the freezer, they were placed onto the rotary 
shaker table, if agitation was required. The agitation speed was set, if required per the 
experimental plan and the bottles were left to thaw. The time of the thawing process 
completion was noted. The ELLAB temperature probes were then removed from the 
bottle and the cap replaced to a cap without holes for probes. Samples were taken from 
the top, middle and bottom of the bottle to assess protein concentration levels at time 
zero (T0). The cap was secured and then the bottle inverted three times to homogenise 
the solution. Additional T0 samples were taken for analysis in centrifuge tubes 
according to the pre-determined sampling plan. These samples were stored at 2 – 8 °C 
prior to analysis. The thawed 125 ml bottle was then placed into an oven, set to 45 °C 
for 4-weeks, with samples taken after 1, 2 and 4-weeks.  
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3.0 RESULTS 
3.1 Formulation Characterisation 
A range of analytical techniques were established to investigate their ability to 
determine Protein Y characteristics and physical instability. 
 
3.1.1 Modulated Differential Scanning Calorimetry (DSC) 
Figure 3-1 displays representative DSC thermograms for Protein Y FDS and the 
dilution buffer, with attempted determination of glass transition temperature. A subtle 
inflexion can be observed in the dilution buffer solution at approximately -30 °C, 
which is not as prominent in the FDS, therefore it was not thought to be the glass 
transition point for Protein Y. This thermal event corresponds with the glass transition 
temperature of sucrose (Wang, 2000), which is the major excipient in the formulation 
and therefore it would be more detectable in the absence of Protein Y. Thermograms 
for the FDS did not exhibit any thermal events prior to the major endotherm that 
occurs with the melt indicating that the glass transition temperature occurs within this 
thermal event. An inflexion point within the melt endotherm was determined using the 
TA universal analysis revealing a possible glass transition around -6 to -10 °C. 
However, due to its very subtle effect in comparison with the heat flow associated 
with the melt of the FDS, a confirmation of the glass transition temperature was 
required by employing a second characterisation technique, freeze-drying microscopy.   
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Figure 3-1: Representative DSC thermograms for Protein Y FDS and dilution buffer  
 
3.1.2 Freeze Drying Microscopy (FDM) 
No major collapse was observed in any of the FDM runs until approximately -12 °C, 
with further progression of withdrawal of the ice boundary until melt started to be 
observed at around -4 °C (Figure 3-2). These observations support the findings from 
the DSC thermograms that the glass transition midpoint occurs at approximately -8 °C.  
Based on the characterisation of the FDS and its thermodynamic behaviour, a storage 
temperature of -20 °C or lower would appear appropriate to ensure the stability of the 
protein. 
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Temperature, 
°C 
Run I 
Freezing to -60 °C,  
10 minutes hold  
Run II 
Freezing to -30 °C, 
10 minutes hold  
Run III 
Freezing to -30 °C, 
30 minutes hold  
-24 
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-12 
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Figure 3-2: Images of Protein Y FDS at -16 to -4 °C for three FDM runs  
Start of 
collapse 
Melt 
started 
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3.1.3 Evaluation of pH Change in Dilution Buffer upon Freezing 
Protein Y FDS is specified to have a pH of 5.7 – 6.3 at 2 – 8 °C. Universal Indicator 
solution was added to samples of the dilution buffer and placed in storage at -80 °C,  
-20 °C, +5 °C (refrigerator) and at a controlled room temperature for 2 days. Despite 
the frosted appearance of the frozen samples, there was no visibly determinable 
change in the colour of the samples. All samples exhibited an orange colour, 
indicating the pH of approximately 6 for the dilution buffer solution and its 
effectiveness at minimising pH shifts during freezing of the FDS (Figure 3-3). In 
addition, the pH of the non-frozen solutions was measured and found to have a pH of 
6.1 and 5.9 for the refrigerated and the room temperature samples, respectively. For 
the purpose of a visual comparison, the pH of the room temperature sample was 
increased using 0.1 M NaOH and measured with a pH meter to calibrate the colour 
change observed. At pH 6.4, the solution was observed to start turning from orange to 
green and at pH 6.8 the solution colour had turned green, as shown in Figure 3-3. 
-80 °C   -20 °C    +5 °C 
(pH 6.1) 
Room 
Temperature 
(pH 5.9) 
Room 
Temperature 
(adjusted 
pH 6.4) 
Room 
Temperature 
(adjusted 
pH 6.8)  
  
Figure 3-3: Visual assessment of pH change for dilution buffer solution following storage at four 
different storage conditions for 2 days 
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3.2 Protein Y Characterisation Studies 
3.2.1 Differential Scanning Calorimetry (DSC) 
The suitability of the DSC technique to detect protein unfolding temperature was 
assessed for FDS samples diluted to 15 mg/ml (FDS-15) and FDS samples with high 
protein concentration of 150 mg/ml (FDS-150). Samples of dilution buffer were also 
assessed as a negative control. Representative thermograms have been plotted in  
Figure 3-4.  
In order to optimise the DSC method, the following changes were made: 
 The sample volume was reduced from 20 μl to 10 μl to minimise the risk of the 
sample pan bursting open at higher temperatures 
 The equilibration and ramp start temperature was changed from 25 °C to 40 °C to 
minimise the run time 
 The end temperature was reduced from 100 °C to 96 °C also to minimise the risk 
of the pan bursting 
No endothermic peak was observed in the dilution buffer. The thermograms for the 
FDS-15 sample did exhibit a small endotherm at the same temperature as for the FDS-
150 thermogram but was significantly less defined. Therefore, FDS with a protein 
concentration of 150 mg/ml was deemed suitable to be used for DSC analysis of 
protein unfolding temperature. 
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Figure 3-4: DSC thermograms of dilution buffer, Protein Y FDS-15 and Protein Y FDS-
150. Temperature ramp 2 °C/ minute and 20 μl sample size. 
 
Increasing the ramp rate from 2 °C/min to 10 °C/min was then investigated to see if 
this would increase the intensity of the endotherm occurring at around 80 °C for the 
150 mg/ml samples (FDS-150). Representative thermograms are displayed in Figure 
3-5. Also, to investigate if improved resolution of the thermal event could be obtained 
by using a ramp rate slower than 2 °C/min, thermograms were obtained with a slower 
ramp rate of 0.5 °C/min and 1 °C/min, with representative thermograms also displayed 
in Figure 3-5 for comparative purposes. The higher ramp rate 10 °C/min resulted in a 
less stable baseline, making it harder to integrate the enthalpy involved with the 
endothermic peak, although determination of the mid-point temperature was still 
precise with the onset and midpoint shifting upwards by approximately 3 °C. 
Temperature ramps slower than 2 °C/min resulted in the diminution in onset and mid-
point of the endotherm, with decrease in ramp rate but no significant improvement in 
repeatability of the enthalpy determination was observed.  
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Figure 3-5:  DSC thermograms of Protein Y FDS-150. Temperature ramp 0.5, 1, 2 and 10 °C / 
minute and 10 µl sample size. 
 
Our finding showed that the optimised DSC standard ramp method was able to 
qualitatively identify an endotherm around 80 °C, at ramp rates from 0.5 – 10 °C/min, 
with the optimum ramp rate appearing to be at 2 °C/min.  
   
3.2.2 Dynamic Light Scattering (DLS) 
An initial DLS analysis was performed to see if freezing and thawing of Protein Y 
altered its size. The Z-average for the size distributions ranged from 10 to 22 nm 
(Figure 3-6). Corresponding polydispersity (PdI) values ranged from 0.16 to 0.76, 
with lower concentrations having a higher PdI value. The high variation in PdI was 
due to use of a default viscosity value of 0.88 mPaS, instead of the actual viscosity 
value for the respective concentration. There was no significant difference observed 
between Z-average for control or freeze-thaw samples. 
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Figure 3-6: Concentration effect on Z-average of Protein Y for samples before and after a freeze-
thaw cycle (default viscosity of 0.88 mPaS) 
 
Figure 3-7 shows the viscosity data referred to in Section 2.3.2.3, where the viscosity 
increases at concentrations above 15 mg /ml. Based on this data an optimum protein 
concentration of 15 mg/ml was selected for the DLS method and viscosity value used 
in DLS analysis changed to 1.4 mPaS. 
  
Figure 3-7: Viscosity of Protein Y solution at different concentrations and 25 °C 
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The initial DLS displayed in Figure 3-6 was reprocessed based on the viscosities 
determined at the respective concentrations (Figure 3-7). This lowered the Z-average 
values to a range between 1 to 14 nm and more importantly showed a divergence in 
the Z-average values for the freeze-thaw samples and the control at the respective 
concentration (Figure 3-8). This finding further confirmed 15 mg/ml as a suitable 
protein concentration for DLS analysis. 
  
Figure 3-8: Concentration effect on Z-average of Protein Y for samples before and after a freeze-
thaw cycle (Corrected viscosity for each concentration) 
In order to determine if the DLS method can detect changes in protein aggregation, 
Protein Y samples were aged and analysed by DLS both unfiltered and filtered to 
assess any effect of filtration. No significant change was observed in Z-average the 
control and the 40 °C sample. However, Z-average of the 80 °C aged sample was 
significantly increased (Figure 3-9). In addition, a more gradual increase in PdI was 
observed as shown in Figure 3-10. There was no significant difference in PdI between 
filtered and unfiltered samples for the control and 80 °C aged sample, however a 
significant effect of filtration was observed for 40 °C aged sample. A second peak at a 
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mean size of 1112.8 nm and a mean intensity of 7.9% was observed only for unfiltered 
sample at 40 °C. 
Based on the large size and low intensity of this peak, it is thought that filtration is still 
appropriate, to remove potential noise from extraneous particles.  
  
Figure 3-9: Protein Y DLS Z-average at a range of temperatures before and after filtration 
  
Figure 3-10: Protein Y DLS PDI at a range of temperatures before and after filtration 
Use of DLS was proven as a suitable method to determine changes in aggregation of 
the Protein Y in the nano-/sub-micron ranges (1 – 1000 nm).  
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3.2.3 Circular Dichroism Spectroscopy (CD)/UV-Absorbance 
In general, peak wavelength increases as the polarity of the microenvironment 
decreases. Due to the presence of L-histidine in the dilution buffer solution used in the 
Protein Y formulation, the FDS is very polar and excipient interference is expected in 
the far-UV region (250 – 190 nm). Therefore, focus was maintained on development 
of a characterisation method in the near-UV region (315 – 250 nm). 
The optimum concentration for measurement was found to be 0.75 mg/ml, which gave 
a UV absorbance of <1.5 absorbance units at 280 nm. However, the CD spectra were 
very noisy and therefore further optimisation of the step and time per point values was 
performed with optimum values being obtained at 1.0 nm and 5 seconds as shown in 
Figure 3-11 and Figure 3-12, respectively.  
 
Figure 3-11: CD spectra for 0.75 and 1.0 mg/ml Protein Y; 1 nm step / 5 seconds per time point 
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Figure 3-12: UV absorbance spectra for 0.75 and 1.0 mg/ml Protein Y; 1 nm step /5 seconds per 
time point  
To see if the developed method could detect changes in the tertiary structure of Protein 
Y, the method was run with a temperature ramp, with spectra recorded at 20, 40, 60 
and 80 °C, as displayed in Figure 3-13. No significant change was observed from 20 
°C to 60 °C. However, there was a dramatic change noted in the CD spectra at 80 °C 
with most of the spectral peaks having flattened. The change in CD spectra at 80 °C 
corresponds with thermal events observed with DSC, indicating unfolding of the 
protein at 75 - 80 °C. 
  
Figure 3-13: Protein Y CD spectra with change of temperature 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
250 260 270 280 290 300 310
Ab
sor
ba
nce
 un
its
Wavelength (nm)
Buffer 1.0 mg/ml 0.75 mg/ml
‐10
‐9
‐8
‐7
‐6
‐5
‐4
‐3
‐2
‐1
0
250 260 270 280 290 300 310
CD
 (m
v)
Wavelength (nm)
20 °C 40 °C 60 °C 80 °C
47 
 
3.2.4 Fluorescence Spectroscopy 
Intrinsic fluorescence spectroscopy was employed to study FDS containing Protein Y 
at a range of protein concentration (150 mg/ml – undiluted, and subsequently dilutions 
down to 0.15 mg/ml), with excitation at 295 nm. The optimum concentration, giving a 
corrected intensity ratio of around 2,000,000 units was obtained at 1 mg/ml. The 
excitation was adjusted to 280 nm in order to maximise the intensity for tryptophan 
residues. 
Optimum slit widths were investigated to determine the best setting that provided a 
corrected intensity ratio of less than 2,000,000 units, as shown in Figure 3-14. An 
optimum corrected intensity ration was determined by setting both excitation and 
emission slit widths to 1.5 nm. 
 
Figure 3-14: Intrinsic fluorescence spectra of Protein Y at 0.75 mg/ml measured at a range of slit 
settings and excitation wavelength at 280 nm 
 
The temperature ramp exhibited decrease in corrected intensity ratio with increase in 
temperature but with no change in λmax until the sample spectra at 80 °C, which 
demonstrated an increased shift in the lambda max from 324 nm to 333 nm. When the 
heated sample was cooled back to 20 °C, the corrected intensity ratio had increased 
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significantly beyond what it originally was at 20 °C but the λmax remained at 333 nm 
(Figure 3-15).   
 
Figure 3-15: Protein Y fluorescence spectra at temperatures from 20 – 80 °C and a sample heated 
to 80 °C and cooled to 20 °C 
 
Intrinsic fluorescence appeared to be capable detecting changes in the structure of 
Protein Y.  
 
3.3 Freeze-Thaw Studies 
Based on initial knowledge gathered from characterisation of the formulation and the 
selection of analytical methods that can detect perturbations in the structure and 
aggregation of Protein Y, a DoE study was conceived to achieve the aim of evaluating 
potential parameters that could cause change in structure or aggregate levels in the 
formulated drug substance. 
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As outlined in the Section 2.3.3, the DoE design generated a plan of eight runs, with 
the sequence listed in Table 2-8. The results of the DoE study are summarized and 
presented into the following sections: 
 The effect of critical parameters on the freezing and thawing temperature 
profiles  
 The effect of freeze/thawing process on Protein Y stability, immediately after 
thaw (time zero, T0) 
 The effect of freeze/thawing process on Protein Y stability over 4 weeks at 
accelerated storage at 45 °C. 
The techniques described in Sections 2.3.1 and 2.3.2 were used to generate responses 
in order to establish predictive models for the attributes analysed. The following 
criteria were set to determine whether the respective response can be used to predict 
and optimize the process for the responses evaluated: 
 The P-Value must be <0.05 for the model to be significant 
 2-level interactions between factors were only included if they improved model 
significance. Also, non-significant variables were included in the model if 
required to support hierarchy 
 Predicated R-squared (R2) is a measure of the amount of variation in new data 
explained by the model, the more terms (or predictors) in the model, the higher 
the predicted R2. Adjusted R2 is the fit adjusted for the number of parameters in 
the model relative to the number of points in the design. It will only increase in 
value if the newly added predictor enhances the model. To ensure the predicted R2 
has good descriptive power it must be within 0.2 of the adjusted R2 
 Adequate precision is a ratio of the predicted result relative to the average 
predicted error value for the model. Adequate precision should be greater than 4 
for use in determination of model discrimination 
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 In some cases, data transformation was required, based on the data as indicated by 
a Box-Cox evaluation within the DoE software. For example, to process negative 
values for freezing temperature rates or for time-based responses, where the data 
can only increase. If data transformation was required, the transformation method, 
lambda (power value) and constant (k) are included in the respective significant 
parameter effect table.  
If the above criteria were satisfied for a respective response, a model R2 and 
significant parameter effect table has been included summarising the overall fit (R2) 
and significant factors in the model. Single level factors with significant effect in a 
model are indicated by black ‘+’ or ‘-’ symbols in the respective model summary 
tables. For visualisation purposes, a relative indication of the parameter contribution is 
indicated by blue shading related to the F-value for the respective significant 
parameter, with darker blue showing a bigger effect (Table 3-1). In some cases, single 
factors are included in the model to support model hierarchy, although the single level 
factors may not be significant. These have been indicated in the model summary tables 
in bracketed red ‘+’ or ‘-‘ symbols. If the factor was not selected in the model, this has 
been indicated with a ‘0’. 
Table 3-1: Shading key for significant parameter F-value in model summary tables 
Significant model 
parameter F-value 
Shading in significant 
parameter table 
0 - 20 
20 - 50 
50- 100 
100 - 200 
>200 
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3.3.1 Temperature Profile Results 
Temperature data was gathered using ELLAB double Smartflex probes as per the 
experimental design, with the one probe located at the bottom inside edge of the bottle 
(‘bottom’) and the other probe located towards the top and centre of the FDS (‘top’). 
To provide an initial understanding of freeze-thaw process times, an average freeze 
and thaw rate was determined for each run simply based on the time taken for the 
difference in temperature the FDS experienced during freeze and thaw respectively to 
reach set-points. These values are shown in Table 3-2. The temperature data has been 
broken down into the freeze and thaw steps and further discussed in Sections 3.3.1.1 
and 3.3.1.2. 
 
Table 3-2: Key temperature and time data from freeze-thaw runs 
Run 
Temperature 
of FDS when 
placed into 
freezer (°C) 
Time from 
freezer 
entry to set 
point 
(hh:mm) 
Overall 
freezing 
rate (°C / 
minute) 
Temperature 
of FDS when 
removed for 
thawing (°C) 
Time from 
freezer 
removal to 
15 °C 
(hh:mm) 
Overall 
thaw rate 
(°C / 
minute) 
1 11.37 04:30 -0.12 -23.25 02:59 0.21 
2 10.09 03:00 -0.47 -26.41 13:52 0.05 
3 20.02 06:27 -0.24 -23.95 08:50 0.07 
4 14.05 13:32 -0.04 -23.14 03:54 0.16 
5 11.22 06:59 -0.21 -80.65 03:56 0.41 
6 11.22 04:37 -0.11 -80.05 10:40 0.15 
7 10.25 13:58 -0.04 -75.89 13:53 0.11 
8 11.50 02:03 -0.70 -78.82 03:47 0.41 
 
The overall freezing rate was determined by the time taken for the top probe in the 
bottle to reach the respective freezer set point, as this was deemed to be the last point 
to freeze. Although a -80 °C freezer was used in the DoE, two of the four runs where 
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FDS was initially frozen using this freezer did not reach the freezer set-point (run 2; -
75.0 °C and run 3; -73.9 °C). Therefore, a value of -75 °C was used for the purposes of 
determining overall freezing rate and post-cooling rates to be consistent across all 
runs. 
The overall thawing rate was determined by the time taken for the top probe in the 
bottle to go from temperature at time of removal from the freezer to reach 15 °C, as 
this was shown to be the last point to thaw. This temperature was chosen as it was a 
minimum temperature that was recorded for all runs after thaw. The overall freeze and 
thaw rates across all three phases for each run are shown in Figure 3-16. 
  
Figure 3-16:  Freeze/thaw rates by run 
 
3.3.1.1 Freezing 
The full freezing profiles determined by the temperature probes at the top and bottom 
of each container for freeze are illustrated in Figure 3-17 and Figure 3-18, 
respectively. The area highlighted in Figure 3-18A is displayed in Figure 3-18B, 
indicating exothermic changes in temperature observed by the bottom probe. 
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Figure 3-17: Freezing profile of FDS measured by the top probe for each DoE run  
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B 
 
Figure 3-18: Freezing profile of FDS. A: Measured by the bottom probe for each DoE run, and B: 
Displaying insert area highlighted in A showing nucleation exotherms 
 
It is interesting to note the temperature at the bottom of the bottle does exhibit a rise in 
temperature (exotherm) as shown in Figure 3-18B, which is indicative of ice 
nucleation.  
Surrounding the FDS bottle with co-loaded bottles (runs 3, 4, 5 and 7) was shown to 
have a significant effect on the time to reach freezer set point. The extended time was 
due to a plateau occurring at temperatures between -1 to -8 °C and is considered as the 
‘actual’ freezing time, as the plateau is the result of the time it takes for the latent heat 
of fusion to be removed, as water is converted into ice (Padala et al., 2010). As 
expected, freezing temperature also had a significant effect on the freezing behaviour. 
Bottles frozen in a -80 °C freezer (runs 2, 3, 5 and 8) had a shorter time to reach the 
final temperature, hence a faster freeze rate. 
Expanding on this approach, the freezing profiles were broken down into three 
different phases: pre-cooling, freezing and sub-cooling (López-Leiva and Hallström, 
2003; Radmanovic et al., 2013). The freezing phase was defined as having initiated 
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when a rate of change in temperature of greater than -0.10 °C/min was observed for 
three consecutive minutes or, in the event that there were less than three readings, then 
the freezing time was taken as 1 or 2 minutes, as applicable. The freezing phase was 
defined as having been completed when the temperature change returned to being 
lower than -0.10 °C/min. This freezing period resulted in a ‘plateau’ in temperature. 
Values for pre-cooling rate, freezing time and sub-cooling rate are shown in Table 3-
3. 
Table 3-3: Freezing phase times and rates 
Run 
Time from 
freezer 
entry to 
plateau 
(pre-
cooling) 
(hh:mm) 
Pre-cooling 
rate 
(°C / 
minute) 
Freezing time 
(plateau) 
(hh:mm) 
Time to go from 
plateau to 
freeze set point 
(sub-cooling) 
(hh:mm) 
Sub-cooling 
rate (freeze 
rate from 
plateau to set 
point)  
(°C / minute) 
1 00:35 -0.39 02:12 01:42 -0.17 
2 00:17 -1.06 00:01 02:41 -0.42 
3 00:51 -0.47 02:09 03:26 -0.34 
4 01:42 -0.16 09:23 02:26 -0.12 
5 00:41 -0.37 02:08 04:09 -0.29 
6 00:36 -0.40 02:26 01:34 -0.18 
7 01:32 -0.13 09:54 02:32 -0.12 
8 00:09 -2.15 00:01 01:52 -0.60 
 
The duration of the freezing plateau was capable of being described by a statistically 
significant model (P-value 0.0001), with the model heavily influenced by the 
significant parameters of presence of co-load bottles surrounding the FDS bottle as 
well as the freezer temperature. 
The pre-cooling and sub-cooling rates of change in temperature were also described by 
statistically significant models (P-values of 0.0005 and 0.0001 respectively), with both 
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freezer temperature and freeze co-load being significant factors for both responses. As 
expected, freeze equilibration, thaw co-load and agitation speed did not have any 
significant contribution to the models for freezing rates and times and were not 
selected in the models. A summary of significant parameters for all freezing 
parameters is shown in Table 3-3. It should be noted that, as the change in 
temperature for a freezing process decreases, a negative rate occurs which required 
data transformation to allow analysis in the DoE. This has been described in Table 3-
4, where applicable. 
Table 3-4: Combined model R2 and significant parameter effect for freezing times and rates  
 
Model 
R2 
Freezing 
temperature
Freeze 
co-load
Freezing 
equilibration 
Thaw 
co-load 
Agitation 
speed 
Pre-cooling rate 
(power, lambda: 
1.95, k: 1.0593) 
0.9505 
+ - 0 0 0 
Freezing time 
(plateau) 
0.9949 
+ - 0 0 0 
Post-cool rate after 
plateau (lambda: 1, 
k: 0.763342) 
0.9690 
+ - 0 0 0 
Overall time to get 
to set point 
(inverse square 
root, lambda: -0.5) 
0.9374 
- + 0 0 0 
 + positive interaction; - negative interaction 
 
Interestingly, the onset of the ice nucleation event shown in Figure 3.18, displays an 
exponential relationship with the pre-cooling rate, which has been shown in Figure 3-
19. A faster cooling rate resulted in an earlier onset of the exotherm. However, there is 
no clear relationship for the magnitude (change in temperature) to cooling rate. 
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Figure 3-19: Relationship between ice nucleation onset time and pre-cooling rate 
 
3.3.1.2  Thawing 
The full thawing profiles determined by the temperature probe at the top and bottom of 
each container are illustrated in Figure 3-20 and Figure 3-21, respectively. 
 
Figure 3-20: Thawing temperature profile of FDS measured by the top probe for each DoE run  
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Figure 3-21: Thawing temperature profile of FDS measured by the bottom probe for each DoE 
run  
 
Surrounding the FDS bottle with co-loaded bottles was shown to have a significant 
effect on overall thaw time, resulting in a plateau in temperature between 0 to 3 °C, 
where the ice melt occurs. The time to thaw was also affected by whether agitation 
was used or not, with agitation resulting in reducing a thawing time by 1 and up to 4 
hours for single and co-loaded bottles, respectively. 
Similar to freezing parameters, the thawing step was broken down into three sub-
phases: pre-thawing, thawing (temperature plateau) and post-thaw and the values are 
presented in Table 3-5. For the purposes of analysis, the plateau was defined as when 
the rate of increase in temperature was less than 0.10 °C/ minute.   
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Table 3-5: Thawing phase times and rates 
Run  
Time from 
freezer removal 
to thaw plateau 
(hh:mm) 
Pre-thaw 
rate (°C / 
minute) 
Thaw plateau 
time 
(hh:mm) 
Time from 
thaw plateau 
to 15 °C 
(hh:mm) 
Post-thaw 
rate (°C / 
minute) 
1 00:38 0.62 01:33 00:47 0.31 
2 04:36 0.10 06:40 02:35 0.08 
3 01:09 0.36 05:45 01:55 0.12 
4 00:42 0.61 01:49 01:22 0.15 
5 01:06 1.22 01:33 01:16 0.20 
6 01:53 0.72 06:21 02:25 0.10 
7 02:00 0.64 08:11 03:42 0.06 
8 01:01 1.33 01:18 01:27 0.15 
 
Thaw plateau time was found to be heavily influenced by the presence of co-load 
bottles (runs 3, 4, 6 and 7) surrounding the FDS bottle during thawing (P-value of 
0.0001). Statistically significant models were generated to describe both pre-thaw and 
post-thaw phases (P-values of 0.0005 for initial thaw rate and 0.0027 for thaw rate, 
post-plateau). Freezing equilibration temperature and thaw co-load were both 
significant factors within the model for pre-thaw rate. Thaw co-load and agitation 
speed were both significant factors for the post-thaw rate. A statistically significant 
model was also generated for prediction of overall thaw time (P-value 0.0017) with 
thaw co-loading and agitation speed selected as significant parameters. Freezing 
equilibration temperature was selected as a non-significant factor in the overall thaw 
time to support model hierarchy. As expected, freezing temperature and freeze co-load 
did not have any significant contribution to the model for thawing rates and times and 
were not selected in the models. A summary of significant parameters for all freezing 
parameters is shown in Table 3-6. 
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Table 3-6: Combined model R2 and significant parameter effect for thawing responses 
 
Model 
R2 
Freezing 
temperature 
Freeze 
co-load 
Freezing 
equilibration 
Thaw  
co-load 
Agitation 
speed 
Pre-thaw rate 0.9512  0  0 - + 0 
Thaw plateau time 0.9412  0  0 0  - 0 
Post-thaw rate 
plateau (inverse 
square root, 
lambda: -0.5) 
0.9057 
 0  0  0 - - 
Overall time to 
thaw (square root, 
lambda: 0.5) 
0.9993 
 0 0  (-) - - 
+ positive interaction; - negative interaction; (-): non-significant negative interaction 
 
3.3.2 DoE Results – Post Thaw 
3.3.2.1 Cryo-Concentration 
3.3.2.1.1 UV Absorbance  
Samples were taken from the top, middle and bottom of the FDS immediately after 
completion thawing, taking care not to disturb the solution during sampling. Each 
sample was diluted to 0.75 mg/ml and UV absorbance spectra were generated.  
An assessment of the variation in protein concentration was made by comparing UV 
absorbance at the scan maxima of 280 nm (A280). Run 8 had the lowest variation in 
A280 values, with Run 4 exhibiting the highest variation. The A280 from top, middle 
and bottom of each run are displayed in Figure 3-22. 
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Figure 3-22: Assessment of Protein Y cryo-concentration by UV absorbance and %RSD at 280nm 
vs sample locations in bottle 
  
Cryo-concentration was assessed by analysing the variability in UV absorbance at 280 
nm (A280) from samples taken from top, middle and bottom of the FDS, immediately 
post-thaw. A statistically significant model was generated (P-value 0.0109), with 
freezing co-loading as a significant factor; where the FDS bottle is surrounded by co-
loaded bottles a higher variation in A280 values from top to bottom of the FDS was 
observed (Table 3-7). As presence of co-loaded bottles also significantly affects all 
phases of freezing, it is thought that a slower freezing rate results in a higher protein 
concentration at the bottom of the bottle and therefore higher variability. 
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Table 3-7: Combined model R2 and significant parameter effect for variation in A280 across top, 
middle and bottom of FDS 
 
Model 
R2 
Freezing 
temperature 
Freeze 
co-load 
Freezing 
equilibration 
Thaw 
co-load 
Agitation 
speed 
A280 –variation 
(%RSD) post-
thaw 
0.6876 
0 - 0 0 0 
- negative interaction 
 
3.3.2.2 Protein Unfolding 
3.3.2.2.1 Differential Scanning Calorimetry (DSC) 
Protein unfolding was assessed using DSC method developed (Section 3.2.1) and the 
results for unfolding onset and mid-point temperature are shown for each run in Table 
3-8. 
Table 3-8: DSC unfolding onset and midpoint temperatures for Protein Y post-thaw (± standard 
deviation) 
 
Mean Unfolding Onset 
Temperature (°C) 
Mean Unfolding Mid-
Point Temperature (°C) 
Bulk control 75.2 (±0.12) 81.1 (±0.05) 
Run 1 75.2 (±0.11) 81.1 (±0.05) 
Run 2 75.2 (±0.28) 81.1 (±0.14) 
Run 3 75.3 (±0.06) 81.2 (±0.12) 
Run 4 75.5 (±0.24) 81.2 (±0.08) 
Run 5 74.9 (±0.11) 81.2 (±0.00) 
Run 6 75.0 (±0.11) 81.2 (±0.05) 
Run 7 75.2 (±0.09) 81.3 (±0.09) 
Run 8 74.8 (±0.41) 81.3 (±0.09) 
 
There was only slight change noted in the onset or mid-point of the unfolding 
temperature for Protein Y across all runs. The DoE was able to generate a statistically 
significant predictive model for unfolding onset temperature (P-value 0.0089), which 
exhibited greater variation than mid-point temperature. Freezer temperature, freezing 
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co-load and freezer equilibration temperature were all statistically significant factors 
within the model for unfolding on-set temperature (Table 3-9).  
Table 3-9: Combined model R2 and significant parameter effect for unfolding onset temperature 
by DSC 
 
Model 
R2 
Freezing 
temperature 
Freeze 
co-load 
Freezing 
equilibration 
Thaw 
co-load 
Agitation 
speed 
DSC unfolding 
onset 
0.9303 
+ - + 0 0 
+ positive interaction; - negative interaction  
 
3.3.2.3 Protein Tertiary Structure  
3.3.2.3.1 Circular Dichroism (Near-UV) 
Circular dichroism spectra were generated in triplicate and averaged for each sample 
as per the parameters developed for the method (3.2.3). The average spectra obtained 
for each sample from each run is shown in Figure 3-23. 
 
Figure 3-23: Averaged circular dichroism spectra normalised against respective A280 and then 
aligned based off CD value at 315 nm 
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The spectra were examined qualitatively and were not analysed as a response in the 
DoE. The shape of the spectra for all runs appear consistent, with the greatest area of 
variation appears to be between 270 nm and 280 nm, which is an area of the spectra 
attributed to tyrosine residues (Kelly et al., 2005).  
 
3.3.2.3.2 UV Absorbance 
UV absorbance spectra were also measured. The average spectra obtained for each 
sample is shown in Figure 3-24.  
 
Figure 3-24: UV absorbance spectra of Protein Y FDS following freeze/thaw for each DoE run of 
DoE  
 
The 1st and 2nd derivatives of the near-UV absorbance spectra were generated using 
Origin software and are displayed in Figure 3-25 and Figure 3-26 below. 
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Figure 3-25: First derivative UV absorbance spectra of Protein Y FDS following 
freeze/thaw for each DoE run  
 
Figure 3-26: Second derivative UV absorbance spectra of Protein Y FDS following freeze/thaw for 
each DoE run. Peaks associated with tyrosine (Tyr), tryptophan (Trp) and phenylalanine (Phe) 
are identified 
 
In order to analyse the effect of freeze and thaw parameters on the tertiary structure, 
peak height difference of the second derivative UV spectra, corresponding to an 
arbitrary distance from peak to trough can be measured for the three aromatic amino 
C 
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acid residues; tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe). Ratios of 
these distances were generated to assess any changes in the microenvironment of 
Protein Y (Katayama et al., 2005), as illustrated in Figure 3-26. 
Statistically significant models were generated for Tyr/Trp and Tyr/Phe ratios (P-
values of 0.0081 and 0.0083 respectively), with significant factors as indicated in 
Table 3-10. The data indicates that there are subtle changes in the microenvironment, 
with co-loading of bottles at freezing being a significant factor in the peak ratio of 
tyrosine to tryptophan. As reported in Section 3.3.1.1, a slower freezing rate will occur 
with co-loaded bottles. The consequence of a slower freezing rate could result in the 
exposure of tyrosine residues in the core of the protein to become more exposed 
relative to tryptophan and therefore increasing the peak ratio for these two aromatic 
amino acid residues. A slow thaw rate as described by co-loaded bottles could also 
induce the same effect. The model of tyrosine to phenylalanine peak ratio contained 
significant factors for freezing temperature and thaw co-load, as negative interactions, 
indicating that slower freeze and thaw rates will expose tyrosine residues within the 
hydrophobic core of the protein. 
 
Table 3-10: Combined model R2 and significant parameter effect for aromatic amino acid residue 
peak distances as generated by 2° UV spectra 
 
Model 
R2 
Freezing 
temperature 
Freeze 
co-load 
Freezing 
equilibration 
Thaw 
co-load
Agitation 
speed 
UV second derivative 
Tyr/Trp ratio post-thaw 
0.9335 
0  - (-) (-) 0 
UV second derivative  
Tyr/Phe ratio post-thaw 
0.8529 
- 0   0 -  0 
- negative interaction (-): non-significant negative interaction 
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3.3.2.3.3 Intrinsic Fluorescence 
Spectra of intrinsic fluorescence were generated using the Fluoromax FT-4 
spectrometer in triplicate. The averaged spectra are shown in Figure 3-27. 
  
Figure 3-27: Intrinsic fluorescence spectra of Protein Y FDS following freeze/thaw for each DoE 
run. 
 
The fluorescence spectra were analysed for shifts in the wavelength at which 
maximum intensity occurred (λmax) and changes in the maximum intensity recorded. 
There was negligible change in the λmax indicating no evidence of unfolding of the 
protein, as shown in Figure 3-28. 
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Figure 3-28: Protein Y maximum fluorescence intensity and corresponding λmax of Protein Y FDS 
following freeze/thaw for each DoE run. 
 
A statistically significant model was generated to describe prediction of intensity for 
the intrinsic fluorescence method post-thaw (P-value: 0.0018), as summarised in 
Table 3-11. Freeze co-load, freezing equilibration temperature, thaw co-load were all 
significant factors for intensity, whilst freezing temperature did not contribute to the 
response variation and was not included in the model. The model for λmax was weaker 
and although a model could be generated with a P-value of <0.05, the predictive power 
as indicated by proximity of predicted R2 to adjusted R2 was not sufficient to allow for 
use.  
Table 3-11: Combined Model R2 and parameter effect for intrinsic fluorescence maximum 
intensity and λmax 
 
Model 
R2  
Freezing 
temperature 
Freeze 
co-load 
Freezing 
equilibration 
Thaw 
co-load 
Agitation 
speed 
Corrected intensity 
ratio post-thaw 
0.9993
0 - + - - 
+: positive interaction -: negative interaction  
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3.3.2.4 Protein Aggregation 
3.3.2.4.1 DLS  
The Z-average and PdI of Protein Y FDS was determined by DLS. The average results 
for Z-average and PdI of each freeze-thaw run are shown in Figure 3-29. 
 
Figure 3-29: Z-Average and PdI of Protein Y FDS following freeze/thaw for each DoE run. 
 
There was only slight variation noted in the Z-average and PdI determined by DLS for 
Protein Y, post-thaw between runs. The DoE was able to generate a statistically 
significant model for PdI (P-value of 0.0054), despite the Run 6 PdI result appearing 
to be an outlier from the predicted PdI value. Agitation speed and freezing 
equilibration were selected as statistically significant factors, with a negative 
interaction, i.e. a higher freezing equilibration temperature and an increased rotational 
speed for agitation, resulted in lower PdI values, post-thaw (Table 3-11). Freezing 
equilibration temperature was included as an experimental factor with the intent of 
studying the effect of change in temperature whilst maintaining the FDS in the frozen 
state. However, from analysis of thawing rates, freezing equilibration temperature is 
also a significant factor in the initial thawing rate as it is the starting temperature for 
the thawing step. Therefore, it appears the variation in the population of species 
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detected by the DLS method from post-thaw samples is linked more to thawing than to 
freezing. 
 
Table 3-12: Combined model R2 and significant parameter effect for DLS Z-average and PDI 
 
Model 
R2 
Freezing 
temperature
Freeze 
co-load
Freezing 
equilibration 
Thaw 
co-load 
Agitation 
speed 
DLS PdI 
post-thaw 
0.8764 
0 0 - 0 - 
- negative interaction 
 
3.3.2.4.2 SEC-HPLC  
HPLC data for purity, high molecular weight (%HMW) and low molecular weight 
(%LMW) species are illustrated in Figure 3-30.   
 
Figure 3-30: Purity, %LMW and %HMW of Protein Y FDS by SEC-HPLC following freeze/thaw 
for each run of DoE. 
 
SEC monomer purity for Protein Y in post-thaw samples varied from 96.6 – 97.0%, 
this variation was primarily driven by variation in percentage of HMW species, which 
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ranged from 1.8 – 2.2%. The percentage of LMW species was less variable, with 
values ranging from 1.1 – 1.3%.  
Overall, SEC-HPLC data indicated less variability than DLS, with no statistically 
significant model being generated that satisfied the criteria outlined in the Section 3.3. 
The model for %HMW was statistically significant indicating freezing equilibration 
temperature as a significant factor, however the P-value was only slightly <0.05 
(0.042) and predicted R2 was not in agreement with adjusted R2 (0.431 versus 0.813). 
 
3.3.3 Stability Studies  
3.3.3.1 Protein Unfolding 
3.3.3.1.1 Differential Scanning Calorimetry (DSC) 
Samples for each run stored at 45 °C were analysed by DSC after 4 weeks. The results 
for unfolding onset and mid-point temperature are shown for time zero (T0) and week 
four (T4) samples of each run in Table 3-13. No significant change was observed in 
unfolding onset or mid-point, indicating that variation in freeze and thaw process 
parameters studied do not have an impact on the accelerated stability of the protein. 
DoE analysis was not performed as only two time points were available and change 
was not significantly different.  
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Table 3-13: DSC unfolding onset and midpoint temperatures of Protein Y FDS following 
freeze/thaw for each DoE run at T0 and T4 weeks storage at 45 °C (± standard deviation, s.d.) 
 
Average Unfolding Onset 
Temperature (°C) (± s.d.) 
Average Unfolding Mid-Point 
Temperature (°C) (± s.d.) 
Weeks at 45°C  T0 T4 T0 T4 
Bulk control 75.2 (±0.12) 75.2 (±0.14) 81.1 (±0.05) 81.1 (±0.06) 
Run 1 75.2 (±0.11) 75.2 (±0.17) 81.1 (±0.05) 81.3 (±0.14) 
Run 2 75.2 (±0.28) 75.1 (±0.21) 81.1 (±0.14) 81.2 (±0.07) 
Run 3 75.3 (±0.06) 75.2 (±0.05) 81.2 (±0.12) 81.2 (±0.16) 
Run 4 75.5 (±0.24) 75.1 (±0.01) 81.2 (±0.08) 81.2 (±0.14) 
Run 5 74.9 (±0.11) 75.2 (±0.18)  81.2 (±0.00) 81.2 (±0.09) 
Run 6 75.0 (±0.11) 74.9 (±0.06) 81.2 (±0.05) 81.2 (±0.09) 
Run 7 75.2 (±0.09) 75.3 (±0.33) 81.3 (±0.09) 81.4 (±0.22) 
Run 8 74.8 (±0.41) 75.3 (±0.34) 81.3 (±0.09) 81.4(±0.12) 
 
3.3.3.2 Protein Tertiary Structure  
3.3.3.2.1 Circular Dichroism (Near-UV) 
Circular dichroism spectra were generated in triplicate and averaged for each sample/ 
time point as per the parameters described earlier. Due to the large number of spectra 
generated, only the averaged spectra obtained for each time point of the bulk control 
and run 5 are shown in Figure 3-31 and 3-32, respectively. 
 
Figure 3-31: Protein Y normalised and aligned CD spectra (near-UV) of bulk control across 4-
weeks storage period at 45 °C 
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Figure 3-32: Protein Y normalised and aligned CD spectra (near-UV); stability DoE Run 5 post 
thaw across 4-weeks storage period at 45 °C 
 
 
The spectra were examined qualitatively to assess any change over 4-week storage 
period at 45 °C and were not analysed as a response in the DoE. There appeared to be 
minimal change in the spectra across each time point. Similar to the spectra post-thaw, 
there were some fluctuations noted between 270 nm and 285 nm, which are regions 
associated with tryptophan and tyrosine residues (Kelly et al., 2005). 
3.3.3.2.2 UV Absorbance 
UV absorbance spectra were equivalent to those generated post-thaw (Section 
3.3.2.3.2). The 1st and 2nd derivatives of the near-UV absorbance spectra were 
generated using Origin software. Representative spectra for the 2nd derivative of the 
bulk control and run 3 are displayed in Figure 3-33 and Figure 3-34, respectively. 
‐8
‐7
‐6
‐5
‐4
‐3
‐2
‐1
0
1
250 265 280 295 310
Cir
cul
ar 
Dic
ho
ism
 (m
de
g)
Wavelength (nm)
Buffer
Run 5 ‐ T0
Run 5 ‐ T1
Run 5 ‐ T2
Run 5 ‐ T4
74 
 
 
Figure 3-33: Second derivative of Protein Y UV spectra of bulk control across 4-weeks storage 
period at 45 °C 
 
Figure 3-34: Second Derivative of Protein Y UV spectra of DoE run 3 post-thaw across 4-weeks 
storage at 45 °C 
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The rate of change in the ratio of peak heights for Tyr to Trp, Trp to Phe and Tyr to 
Phe over 4-weeks were all capable of being described by statistically significant 
models, with P-values of 0.0003, 0.0015 and 0.0067 respectively (Table 3-14).  The 
model for change of tyrosine to tryptophan peak ratio’s contained freeze co-load, 
freezing equilibration temperature, thaw-co-load and agitation speed as significant 
factors. The model for change in the ratio of peak heights for tryptophan to 
phenylalanine contained freeze co-load, thaw-co-load and agitation speed as 
significant factors. The change in the ratio of peak heights for tyrosine to 
phenylalanine was also able to be described with a model containing freeze co-load, 
thaw-co-load and agitation speed as significant factors. Interestingly, freezing 
temperature was found not to be a significant factor in any of the three models for rate 
of change in amino acid peak ratios.   
Table 3-14: Combined Model R2 and parameter effect for change in aromatic amino acid residue 
peak height ratios as generated by 2° UV spectra 
 
Mode
l R2 
Freezing 
temperatur
e 
Freeze 
co-load 
Freezing 
equilibration 
Thaw 
co-
load 
Agitatio
n speed 
UV 2nd derivative 
Tyr/Trp ratio slope 
(power K=0.02474 
and lambda of 1.6) 
0.997
8 
0  + - + - 
UV 2nd derivative 
Trp/Phe ratio slope 
0.980
5 0 - 0 + + 
UV 2nd derivative 
Tyr/Phe ratio slope 
0.987
5 0 0 - + + 
+ positive interaction; - negative interaction 
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3.3.3.2.3 Intrinsic Fluorescence 
Intrinsic fluorescence spectra were generated in triplicate for samples on storage. 
Representative averaged spectra are shown in Figure 3-35 and Figure 3-36 for the 
control and run 6, respectively. 
 
Figure 3-35: Intrinsic fluorescence spectra of Protein Y UV spectra of bulk control across 4-weeks 
storage period at 45 °C  
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Figure 3-36: Intrinsic fluorescence spectra of Protein Y for DoE run 6 across 4-weeks storage 
period at 45 °C  
 
The fluorescence spectra were then analysed for shifts in the wavelength at which 
maximum intensity occurred (λmax) and also changes in the maximum intensity 
recorded. This is illustrated in Figure 3-37 and Figure 3-38, respectively. There was 
negligible change in the λmax indicating that no unfolding of the protein was detected. 
A certain variation in intensity was observed for each run across all time points, but no 
consistent trend was noted by visual analysis of the data.  
 
Figure 3-37: Intrinsic fluorescence λmax by run over 4-weeks storage at 45 °C 
 
 
Figure 3-38: Maximum fluorescence intensity by run over 4-weeks storage at 45 °C 
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For the freeze thaw studies described, there was no significant change observed in λmax 
but there was variation observed in maximum intensity across all runs and time points. 
The DoE was able to attribute the variation in intensity to some of the experimental 
variables for the T0 result but not for the change of intensity over storage time, 
although the level of variation in intensity at each time point was of a similar order of 
magnitude.   
The fluorescence method developed used an excitation wavelength of 280 nm in order 
to generate a maximum intensity response. However, generation of fluorescence 
spectra with excitation of Protein Y at 295 nm would enable a more targeted 
examination of tryptophan residues, as the fluorescence contribution of tyrosine 
residues is diminished at this excitation wavelength per (Hui, Xue, Xuesong, and Yan, 
2015). 
The DoE generated statistically significant models for both change in λmax and in 
maximum intensity over the 4-week storage period at 45 °C. The model for change in 
λmax had an F-value of 8.2 and a p-value of 0.027, with freezing temperature and 
freezing co-load both selected as significant factors. The model for rate of change in 
intensity was weaker, with an F-value of 7.4 and a p-value of 0.042. However, the 
predictive power of the models for both change in λmax and intensity was not 
satisfactory with predicted R2 and not in agreement with adjusted R2 (0.400 versus 
0.672 and 0.388 versus 0.7324 respectively). 
 
3.3.3.3 Protein Aggregation 
3.3.3.3.1 DLS  
The Z-average and PdI of Protein Y FDS was determined by DLS for samples stored 
at 45 °C as per the experimental plan. The average results for the 45 °C stability 
profile of each freeze-thaw run are shown in Figure 3-39 and Figure 3-40. 
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Figure 3-39: Protein Y DLS Z-average by run over 4-weeks storage at 45 °C 
 
Figure 3-40: Protein Y DLS PdI by run over 4-weeks storage at 45 °C  
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Table 3-15. Freezing equilibration temperature and thaw agitation speed were found 
to be significant factors with a positive interaction for both change in PdI and in Z-
average, i.e. a higher value for freezer equilibration temperature and agitation rate 
result in higher rates of change in PdI and Z-average.  
It is interesting to note that the same factors that were significant for DLS Z-average 
and PdI from post-thaw samples are significant for assessment of the rate of change 
observed per week at 45 °C accelerated stability, although the interactions have 
changed from negative to positive. It is thought this can be explained by the increase 
in Z-average and PdI for 45 °C not being truly linear. As can be seen in Figure 3-39 
and Figure 3-40, the variability in Z-average and PdI at T0 reduces at subsequent time 
points. This may indicate that in order to assess the potential longer-term changes 
using accelerated temperatures at 45 °C that it would be more appropriate to analyse 
more points at between time zero and 2-weeks. After the 2-week time point the 
thermodynamic effect of the storage temperature has a greater effect than differences 
attributed to freezing and thawing parameters. 
Table 3-15: Combined model R2 and significant parameter effect for rate of change for Protein Y 
Z-average and PdI by DLS over 4-weeks storage at 45 °C 
 
Model 
R2 
Freezing 
temperature
Freeze  
co-load 
Freezing 
equilibration 
Thaw  
co-load 
Agitation 
speed 
DLS PdI rate of 
change (slope) 
0.8696 
0 0 + 0 + 
DLS Z-average rate 
of change (slope) 
0.9231 
0 0 + 0 + 
+ positive interaction  
 
3.3.3.3.2 SEC-HPLC  
HPLC data for purity, high molecular weight (%HMW) and low molecular weight 
(%LMW) species are illustrated in Figure 3-41, Figure 3-42 and Figure 3-43, 
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respectively, for all runs up to week 2 or 3, and for a subset of samples (bulk control 
run and runs 1- 4) up to the 4-week time point at 45 °C. Trend lines generated for runs 
1-4 indicates that the rate of change in purity, %HMW and %LMW would appear to 
be equivalent across samples for all runs. 
 
Figure 3-41: Protein Y SEC-HPLC % purity by run across 4-weeks storage at 45 °C (with trend 
line for bulk control and runs 1-4) 
 
Figure 3-42: Protein Y SEC-HPLC % HMW by run across 4-weeks storage at 45 °C (with trend 
line for bulk control and runs 1-4) 
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Figure 3-43: Protein Y SEC-HPLC % LMW by run across 4-weeks storage at 45 °C (with trend 
line for bulk control and runs 1-4) 
 
3.4 Scalability of the Data 
To establish a relationship between behaviour in the small-scale model employed in 
this study (87.5 g in 0.125 L container) and the larger production scale volume (3,500 
g in 5 L container), a correlation was sought between 2 factors, surface area to volume 
(SA:V) ratio and freeze time. The SA:V ratio is a related parameter to the freeze path 
length which impacts the resulting freeze time. Containers with higher SA:V ratio 
have shorter freeze path lengths and will therefore freeze and thaw faster (Rayfield et 
al., 2016). A dimensional comparison of the commercial freeze/thaw process for 
Protein Y versus lab scale employed in this study was made (Table 3.16).  
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Table 3-16: Dimensional comparison of commercial versus small scale models 
Attribute 
Commercial 
Scale 
Lab Scale 
(DoE) 
Bottle nominal capacity (L)   5 0.125   
Height (mm) 299 104.6 
Width (mm) 163 49 
Length (mm) 163 49 
Load in bottle (kg)   3.50  0.0875  
Estimated volume in bottle (based on density of 1.083 
g/ml at 20 °C, L) 3.23 0.0813 
Estimated % fill of bottles 65% 65% 
Surface area of base (W x L/1000000, m2) 0.027 0.0024 
Estimated height of fill in bottle (liquid state, mm) 121.6 33.8 
Estimated surface area of bottle(s) in contact with heat 
/cold source (m2) 0.106 0.009 
Surface area to volume ratio (m2/L) 0.033 0.111 
 
As the SA:V ratio reduces, it would be expected that the freeze and thaw time would 
increase. There is no results available on the commercial scale freezing process, 
however thawing at ambient temperature at commercial scale typically takes 
approximately 24 hours to complete. Observations from the small-scale experiments 
relative to the full-scale commercial process showed a significant reduction in thaw 
time, which can be attributed to the smaller SA:V ratio. The SA:V ratio of the 
individual small-scale bottle of formulation studied was 3.36 times larger than the 
ratio for the commercial process. The SA:V ratio can be used as a scaling factor to 
predict freeze and thaw cycle times for commercial scale. The empirical models for 
prediction of time for overall freezing and thawing steps (inclusive of all three 
respective sub-phases) are shown in Table 3-17.  
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Table 3-17: Empirical models for overall freeze and thaw times with predicated R2 and P-value 
for models 
Process 
step 
Co-load / 
Single 
Bottle 
Equation Predicated 
R2 for 
model 
P-
value 
Freeze Co-load ඥ𝑡𝑖𝑚𝑒 𝑡𝑜 𝑓𝑟𝑒𝑒𝑧𝑒 ൌ 29.861 ൅ ሺ0.080 ∗ Aሻ  0.8398 0.001 
Single ඥ𝑡𝑖𝑚𝑒 𝑡𝑜 𝑓𝑟𝑒𝑒𝑧𝑒 ൌ 18.580 ൅ ሺ0.080 ∗ Aሻ 
Thaw Co-load √𝑡𝑖𝑚𝑒 𝑡𝑜 𝑡ℎ𝑎𝑤 ൌ 29.224 ൅ ሺ0.007 ∗ Bሻ
െ ሺ129.290 ∗ Cሻ െ ሺ0.848 ∗ B
∗ Cሻ 
0.9891 0.002 
Single √𝑡𝑖𝑚𝑒 𝑡𝑜 𝑡ℎ𝑎𝑤 ൌ 15.214 ൅ ሺ0.007 ∗ Bሻ
െ ሺ54.269 ∗ Cሻ െ ሺ0.848 ∗ B
∗ Cሻ 
A: Freezer temperature; B: Freezing equilibration temperature; C: Agitation speed 
Figure 3.44 highlights the interactive effect of the co-load (factor ‘C’) with freezing 
temperature (factor ‘A’) on the overall time to freeze.  
 
Figure 3-44: Effect of freezing temperature (Factor A, X-axis) for prediction of overall time to 
freeze (Y-axis); presence of co-loaded bottles (C1: black squares) versus individual bottle (C2: red 
triangles) 
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Figure 3.45 highlights the interactive effect of the co-load (factor ‘D’) with agitation 
speed (factor ‘E’) on the time to thaw. From the error bars in these figures, it can be 
seen that the time is much harder to predict when co-loaded bottles surround the FDS 
bottle in the centre, with freezing time being harder to predict than thaw time.  
 
 
Figure 3-45: Effect of agitation speed (Factor E, X axis) and co-loading (Factor D) for predicated 
overall time to thaw (Y axis); co-loaded bottles (D1: black squares) versus individual bottle (D2: 
red triangles) 
 
The predicted freeze and thaw times based on the models determined for the DoE are 
shown in Table 3-18. The values that have been typically observed at commercial 
scale were determined using the scaling factor to calculate overall times for freeze and 
thaw. However, the range of predicted values, based on the 95% confidence interval 
for the respective models in Table 3-17 also demonstrates the inherent variability in 
uncontrolled freeze and thaw processes. This variability relates to the factors selected 
for the models and make an accurate prediction challenging. Due to the absence of 
accurate data for the commercial freezing and thawing times and the factors, such as 
co-load and ambient temperature influencing these times, it is difficult to determine if 
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these predicted times are accurate. However, the variation in predicted times, are 
heavily influenced by co-load and therefore it would be expected to observe variation 
for freezing and thawing times, at the commercial scale. This variation may be 
amplified at commercial scale based on the smaller SA:V ratio and the distribution of 
the individual containers.   
Table 3-18: Predicted freeze and thaw times for lab and commercial scale using scaling factor of 
3.36 for surface area to volume (SA:V) ratio 
Run  
Observed 
freeze 
time, 
hours 
Observed
thaw 
time, 
hours 
Predicted 
freeze time 
125ml 
bottle, 
hours 
Predicted 
thaw time 
125 ml 
bottle, 
hours 
Predicted 
commercial 
scale freeze 
time based on 
scaling factor, 
hours (95% 
confidence 
interval range) 
Predicted 
commercial scale 
thaw time based 
on scaling factor, 
hours (95% 
confidence 
interval range) 
1 5 3 5 3 16 (5 – 24) 10 (7-11) 
2 3 14 3 14 9 (4 - 14) 47 (43 – 51) 
3 6 9 10 9 32 (22 – 42) 31 (27 – 33) 
4 14 4 13 4 45 (33 – 58) 13 (11 – 15) 
5 7 4 10 4 32 (22 – 42) 13 (11 – 15) 
6 5 11 5 11 16 (10 – 24) 37 (32 – 39) 
7 14 14 13 14 45 (33 – 58) 46 (42 – 50) 
8 2 4 3 4 9 (4 – 14) 12 (10 – 14) 
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4.0 DISCUSSION 
This research project was conceived to perform a high-level experimental assessment 
of the freeze and thaw process for Protein Y FDS in polycarbonate bottles at a reduced 
scale in order to evaluate the factors related to freeze thaw times that could cause a 
change in (1) protein structure and (2) aggregate levels in the formulated drug 
substance. A designed set of experiments (DoE) were executed to estimate the key 
process parameters via the development of empirical polynomial models, which were 
used to predict the influence parameters on freezing and thawing times and protein 
stability. The validity of the models developed at small-scale was also evaluated to 
understand the behaviour of the respective full-scale commercial process. 
4.1 Analytical Methods 
Prior to execution of the DoE a set of analytical methods were established to 
characterise structural changes in the therapeutic protein, focusing particularly on its 
aggregation and tertiary structure. Following evaluation, a range of techniques, CD 
(Near-UV), fluorescence spectroscopy, DSC and DLS were used to characterise 
Protein Y FDS and detect changes in aggregation and tertiary structure of the protein. 
In terms of aggregation, DLS showed better sensitivity to detect changes than SEC-
HPLC but higher variability was observed. Second derivative UV absorption spectra 
showed particularly good discriminative power, relative to the CD spectra and to 
intrinsic fluorescence spectra to determine changes in the tertiary structure of Protein 
Y. Fluorescence method development with Protein Y FDS has shown that thermally 
induced unfolding of the molecule induces an upward shift the wavelength of 
maximum intensity (λmax), indicative of exposure of tryptophan and possibly tyrosine 
residues within Protein Y. Based on the relative emission spectra for the three 
aromatic amino acid residues (i.e. tryptophan, tyrosine and phenylalanine), it would be 
thought that the major contributor would be tryptophan (Hui et al., 2015). However, 
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there is proportionally a larger number of tyrosine residues situated in the hydrophobic 
core of the protein.  
4.2 Freeze-Thaw DoE 
4.2.1 Influence of process parameters on freeze/thaw profiles and Protein Y cryo-
concentration  
 
For all DoE runs, freezing profiles followed a similar profile as those reported in the 
literature, with Protein Y undergoing distinct phases during the freezing process 
(López-Leiva and Hallström, 2003). The approach taken by Radmanovic et al. 
involved the three phases overlapping (Radmanovic et al., 2013), however in the 
experiments described, the phases were divided based on inflexions in rate of 
temperature change. A rate of decrease greater than -0.10 °C/min was used as the 
value to define the freezing time for ice-formation. When the rate of decrease in 
temperature slowed to a value greater than -0.10 °C a ‘plateau’ in temperature occurs, 
whilst ice is formed through the solution. The time taken for freezing plateau 
completion varied across all eight experiments from 1 minute to greater than 9 hours. 
This time was heavily influenced by whether the FDS was co-loaded with other bottles 
and also freezing temperature. Co-loading of bottles was found to be a significant 
factor, resulting in increases to the freeze and thaw time. Therefore, co-loading of 
bottles can be considered as effectively increasing the path length, elongating the time 
for the ice front to reach the centre of the FDS bottle.  
The ice nucleation shown in Figure 3-18, indicates an exponential relationship 
between time to onset of ice nucleation and the pre-cooling rate, which has been 
shown in Figure 3-19.  As described by Singh and Nema, faster onset of nucleation 
should lead to faster ice formation throughout the solution and result in a larger 
surface area of ice (Singh and Nema, 2010). A slower onset therefore results in more 
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gradual ice formation through the bottle and provides the potential for cryo-
concentration to occur.  
Cryo-concentration was assessed by analysing the variability in UV absorbance at 280 
nm (A280) from samples taken from top, middle and bottom of the FDS, immediately 
post-thaw. A statistically significant model was generated, with freezing co-load as a 
significant factor. When the FDS bottle was surrounded by co-loaded bottles, a higher 
variation in A280 values from top to bottom of the FDS was observed. Also, the 
presence of co-loaded bottles was shown to significantly affect all phases of freezing. 
It is thought that a slower freezing rate results in a higher protein concentration at the 
bottom of the bottle and therefore higher concentration variability. Fewer/larger ice-
crystals formed can force the proximity of protein molecules closer to each other. 
Based on the relative lighter density of ice to liquid water, and convective currents 
within the bottle due to the increasing temperature differential between the edge and 
the centre of the bottle, the ice crystals will coalesce towards the top of the solution 
which results in reduced protein concentration at the top of the bottle and increasing at 
the bottom (Singh and Nema, 2010). 
Similar to freezing parameters, the thawing step was broken down into three sub-
phases: pre-thawing, thawing (temperature plateau) and post-thaw. The thaw plateau 
was found to be heavily influenced by the presence of co-load bottles surrounding the 
FDS bottle during thawing. Freezing equilibration temperature and thaw co-load were 
both significant factors within the model for pre-thaw rate, with a lower freezing 
equilibration temperature and no co-loaded bottles resulting in a faster increase in 
temperature. Thaw co-load and agitation speed were significant factors for the post-
thaw rate and the overall thaw time, with faster agitation and single bottles also 
resulting in a faster temperature increase.  
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4.2.2 Protein Y structural changes during freeze/thaw processes 
Structural changes in Protein Y were observed during the freeze-thaw experiments. 
These changes may be a consequence of a more concentrated solution and/or changes 
in the microenvironment of the protein, related to slower freeze and thaw rates (Singh 
and Nema, 2010). 
There was subtle variation noted in the onset or mid-point of the unfolding 
temperature for Protein Y as determined by DSC. The DoE was able to generate a 
predictive model for unfolding onset, which demonstrated more variability than the 
mid-point temperature. Freezer temperature, freezing co-load and freezer equilibration 
temperature were all statistically significant factors within the model for unfolding on-
set temperature, with higher freezing and equilibration temperatures and co-loaded 
bottles resulting in an increased on-set temperature of Protein Y unfolding. The DSC 
thermograms exhibited an initial endothermic event with an onset at around 65 °C. In 
a study by Shah et al. investigating the photo-stability of a monoclonal antibody, DSC 
profiles showed two unfolding events. By comparing with the published DSC 
thermograms of similar IgG1 mAbs, the first peak in the DSC thermogram that occurs 
at lower temperature (with a Tm of ∼71 °C) was attributed to the unfolding of the CH2 
domain and the second larger peak occurring at higher temperatures (with a Tm of 
∼82.5 °C) was attributed to the unfolding of Fab and CH3 domains (Shah et al., 2018). 
It is thought that variation in freeze and thaw parameters are having a similar effect 
occurred with the Protein Y melting behaviour observed in this study. A similar 
finding has been reported by Shah et al., although the initial endothermic event for 
Protein Y is more of an inflexion without a clear peak. However, due to the proximity 
of the initial endothermic event to the main peak with a midpoint at 81 °C, variability 
in the onset of the main peak is being affected by the initial thermal event, thus 
making on-set of the main peak harder to detect.  
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Structural changes in Protein Y were observed by spectroscopy following the freeze-
thaw experiments, both in terms of fluorescence emission intensity and also in terms 
of tyrosine to tryptophan and tyrosine to phenylalanine second derivative UV peak 
height ratios. Statistically significant models were generated for the arbitrary peak 
height ratios for tyrosine to tryptophan and tyrosine to phenylalanine ratios in second 
derivative UV absorbance spectra. The data indicates that there are subtle changes in 
the microenvironment, with co-loading of bottles at freezing being a significant factor 
in the peak ratio of tyrosine to tryptophan. Co-loading of bottles in close proximity to 
each other will result in slower freeze rates. It is thought the increase in tyrosine to 
tryptophan peak height ratios are induced by these slower freeze rates, thus indicating 
the exposure of these aromatic amino acid residues normally in the hydrophobic core 
of Protein Y to the aqueous environment (Katayama et al., 2005). 
Intensity, as determined by intrinsic fluorescence was shown to be a highly sensitive 
technique with a high amount of variation between samples from different freeze/thaw 
regimes.  A statistically significant model was able to predict variation in intensity 
post-thaw. Freeze co-load, freezing equilibration temperature, thaw co-load and 
agitation speed were all significant factors for intensity. The model for fluorescence 
intensity is more complex than second derivative UV but also shows that co-loaded 
bottles during freezing, which shown to result in slower freezing rates results in a 
higher intensity. The model also demonstrates the effect of thawing parameters on 
intensity. A higher freezing equilibration temperature, co-loaded bottles and no 
agitation are all linked to slower thawing rates and also result in an increase in 
fluorescence intensity. The limitation for the fluorescence method is that with 
excitation at 280 nm it is not specific for tryptophan or tyrosine (Hui et al., 2015), so it 
is unknown which of these aromatic residues are causing the change in intensity.    
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4.2.3 Protein Y aggregation during freeze/thaw processes 
The variability of Protein Y particle size was observed during the freeze-thaw 
experiments via the PdI measurements obtained by DLS. The DoE generated a 
significant model for PdI with agitation speed and freezing equilibration emerging as 
statistically significant factors. Negative interactions were determined, i.e. a higher 
freezing equilibration temperature and an increased rotational speed for agitation 
resulted in lower PdI values, post-thaw. It appears the variation in the population of 
species detected by DLS in post-thaw samples was linked more to thawing parameters 
than freezing, as freezing equilibration is more related to the point of starting the thaw 
step than the freezing step itself. The SEC-HPLC data did not fit to a significant model 
with acceptable predictability. 
4.2.4 Protein Y structural changes during post-thaw stability study  
Changes in the structure of Protein Y were assessed during storage at 45°C post-thaw. 
No significant change was observed in unfolding onset or mid-point for samples 
analysed at 4 weeks compared to the post-thaw (T0) value. DSC results did not 
indicate that variation in freeze and thaw process parameters impacted the accelerated 
structural stability of the protein. However, evaluating the change in 2° UV-
absorbance peak height ratios over 4 weeks resulted in statistically significant models 
for tyrosine to tryptophan, tryptophan to phenylalanine and tyrosine to phenylalanine 
peaks.   
No significant models were generated to describe changes in intrinsic fluorescence 
intensity or λmax over 4 week’s storage at 45 °C. Also, significant models were 
generated to describe changes in Protein Y tertiary structure using 2° UV-absorbance 
peak height ratios for post thaw samples. This suggests that the intrinsic fluorescence 
method can detect ‘flex’ in the tertiary structure of Protein Y post thaw, but the 
discriminatory power diminished with longer term storage of the samples. Analysis of 
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2° UV-absorbance peak height ratios proved to be a useful technique for detecting 
structural changes in Protein Y post-thaw and upon storage. 
4.2.5 Protein Y aggregation during post-thaw stability study  
Changes in Protein Y size was assessed during storage of samples of 45°C post-thaw. 
Freezing equilibration temperature and thaw agitation speed were found to be 
significant factors with a positive interaction for both the change in DLS Z-average 
and PdI values over four weeks at 45 °C. This was inverse to the relationship for Z-
average and PdI model for post-thaw samples. Z-average and PdI value measured for 
stability at 45 °C all increased over 4 weeks storage, as would be expected. The rate of 
increase in these attributes between 1 and 2 weeks was most pronounced for the runs 
with lower Z-average and PdI, immediately post-thaw (T0). This apparent change of 
rate effectively ‘inverted’ the effects observed immediately post-thaw.  
 
4.3 Validity of the Small-Scale Model to Understand the Behaviour of the 
Respective Full-Scale Commercial Process 
The scalability of the small-scale experiments to commercial scale can be challenging 
due to the shorter freeze and thaw times. However, DLS and HPLC data support that 
changes in aggregation levels are equivalent between the full-scale control and the 
scaled-down experimental bottles both immediately post-thaw and over 4 weeks 
storage at 45 °C (Figures 3-29 and 3-30). In addition, fluorescence, near-UV CD and 
2nd derivative UV data support that tertiary structure is not significantly affected by the 
differences of scale (Figures 3-23, 3-26 and 3-28).Determination of SA:V ratios for 
laboratory and commercial scale and use of the differential as a scaling factor resulted 
in reasonable prediction of expected freeze and thaw time for the commercial scale. 
While, the simplistic empirical model with a correction factor presented in this study 
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can provide some understanding, a better prediction of freezing time could potentially 
be achieved by the use of the model to determine freezing kinetics based on the 
principles established by Plank (López-Leiva and Hallström, 2003). 
Studies designed to understand and model the freezing processes originally started 
with freezing of food and goes back to work performed by Plank. Originating from the 
basic heat transfer equations (Fourier’s equation for heat transfer by conduction and 
the Prandtl concept of boundary layer for heat transfer by convection), Plank derived 
the following equation (López-Leiva and Hallström, 2003): 
      [Equation 4-1] 
Where:  
 F is freezing time ‘‘according to Plank’’ (sec),  
 ρ is food density (kg/m3),  
 ΔHf represents enthalpy change during freezing step (J/kg),  
 Tf is initial freezing point (°C),  
 Ta is temperature of the freezing medium (°C),  
 d is sample thickness (=h0) (m),  
 h represents heat transfer coefficient (W/m2 °C),  
 λ is thermal conductivity of the frozen food (W/m °C), and  
 P and R are parameters defining the geometry of the food.  
Plank’s analysis concluded that parameters P and R are functions of the geometry of 
the body. For the experiments reported in this thesis, the geometry of Protein Y FDS 
in a bottle, being frozen in a conventional freezer is best represented by a cube, as heat 
transfer can occur from three dimensions. From Planks derived equations the proposed 
P is 1/6 and R is 1/24. The P/R ratio is always equal to four irrespective of the 
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geometry of the shape for regular geometries. The ‘freezing time according to Plank’ 
specifically relates to the freezing plateau, where ice formation occurs.  
Figure 4-1 provides a visual illustration of Protein Y freezing, in a 5 L polycarbonate 
bottles, along with variables to be considered to understand and model the freezing 
and thawing process. 
 
Figure 4-1: Visual graphic of freezing process for 5 L polycarbonate bottles 
 
The freezing time according to Plank will be dependent on the rate of advancement of 
the ice front travelling through the solution, which will be defined by the efficiency of 
heat transfer of the freezing environment in which the solution is frozen. Considering 
the factors described in the Plank equation across the DoE runs, the key variable was 
the temperature of the freeze medium, as all other factors were constant between runs. 
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While the Plank equation can account for the freeze temperature, the factor of co-load 
is not accounted for, and would be difficult to describe and hence model.  
Results highlight the robustness of the FDS to withstand stresses during freezing and 
thawing across DoE runs as demonstrated through the analytical data. This suggests 
that Protein Y is capable of being frozen and thawed through much quicker rates of 
temperature change than the current commercial process, and that faster freezing and 
thawing cycles could improve manufacturing efficiency and cycle times. Furthermore, 
the results show that cryo-concentration and the potential for changes in tertiary 
structure can be minimised with a faster freezing rate. This is consistent with similar 
conclusions reported by Miller et al. (Miller et al., 2013). Application of heat transfer 
through a water bath for thawing could potentially allow for a much quicker thaw. The 
process currently employed is uncontrolled because it relies on air contact as the 
medium for heat transfer/removal. Alternatively, the use of a controlled system, along 
with bag-based storage of the FDS, could allow for a combined system that both 
freezes and thaws the FDS and could increase freeze and thaw rates, as well as SA:V 
ratio.  
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5.0 PROPOSALS FOR FUTURE WORK 
 Investigate additional techniques to study protein aggregation and structural 
changes in freeze thaw samples  
The methods used to detect aggregation of Protein Y in the freeze-thaw experiments 
were SEC and DLS. These two methods can typically only detect particle sizes up to 
100 nm and 500 nm respectively (Hamrang et al., 2015). It would be useful to employ 
a technique which count and classify particles for sizes greater than 500 nm to gain a 
better understanding of the type of aggregation observed. 
Protein aggregates can be classified according to their size as visible (>100 µm), 
micron (1–100 µm), submicron (100–1000 nm), and nanometre particles (<100 nm). 
Aggregates in the micron and submicron size range raise concerns as they are 
potentially immunogenic, could coalesce to form larger particles over time, or function 
as nuclei for further aggregation. Even though the United States Pharmacopeia (USP) 
and the European Pharmacopoeia (Ph. Eur.) currently define concentration limits in 
parenteral solutions only for particles larger than 10 µm, regulatory authorities 
increasingly expect quantitative characterization of micron particles from 1 to 10 µm 
and qualitative characterization of submicron particles from 100 to 1000 nm, in early 
stages of the development phase (Weinbuch et al., 2013). 
The techniques employed in this study were DLS which investigates particle sizes in 
the submicron range and SEC-HPLC which detects protein aggregates <100 nm. A 
study performed by Nidhi et al. compared the ability of Micro Flow Imaging (MFI) to 
detect protein aggregation versus SEC-HPLC during a monoclonal antibody freeze-
thaw study. MFI was capable of detecting aggregated forms in the sub-visible particles 
range of 1-10 µm of protein and was shown to be more sensitive than SEC-HPLC 
(Nidhi et al., 2011). Future work would include MFI as a technique to compliment 
SEC-HPLC and DLS analysis of samples for aggregate detection. Fourier Transform 
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Infrared Spectroscopy (FT-IR) can be used for protein structural characterisation. 
Application is particularly pertinent to analysis of secondary structure in liquid and 
solid state. FT-IR has been widely used to characterise protein structure in precipitates, 
in amyloids and fibrils and in solid lyophilised state. It has also been useful to 
understand the mechanism of non-native aggregation as it can point to conformational 
changes that may take place prior to aggregation (Wang and Roberts, 2010).  In that 
study all analysis of aggregation was performed in the thawed state. It would be 
interesting to study protein conformation and aggregation in the frozen solid state 
using a technique such as FT-IR.  
 
 Establish model based on the Plank equation to determine freezing time and 
investigate its ability to accurately predict freezing time  
The current study developed empirical models to predict freezing time, however 
fundamental theoretical models are considered to be advantageous as they can be 
extrapolated outside the set of experiments used to establish them. The Plank equation 
is a key equation used to predict freezing time and future experimental work is 
required to establish this equation for the freezers studied.   
As described by Radmanovic et al. the freezing process can also be described as a one-
dimensional heat transfer process or alternatively a thermal equilibrium between heat 
transferred by the cooling plates and the heat liberated during ice crystallization 
(Radmanovic et al., 2013).  
t ൌ ୱమ ୐୤ ஡஛ୢ஬           [Equation 5-1] 
where: 
 t is freezing time 
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 Lf represents the latent heat of fusion of the substance being 333.5 kJ/kg for 
water 
 ρ is density of ice being 916.7 kg/m3 at 0 ◦C 
 λ is thermal conductivity of the system 
 dϑ is mean temperature difference between freeze container content and 
cooling plates and is calculated as difference between the mean cooling plate 
temperature over the course of freezing time and 0 ◦C 
 s is pathlength or thickness of the dimensional object 
Using this equation, the duration of freezing can be predicted with just one unknown 
parameter - the thermal conductivity, which can be empirically determined. Thermal 
conductivity depends on the freezing kinetics of the specific freezer and can be 
determined experimentally using water as the freezing medium as the latent heat of 
fusion is well known (333.5 J/g) (Radmanovic et al., 2013). Measurement of the 
temperature profiles and the actual freezer temperature as the water freezes would 
allow measurement of the freezing plateau time for each bottle/freezer combination. 
An overview of experiments to determine thermal conductivity has been outlined in 
Table 5-1. The set of experiments described cover the two freezers used for the 
freeze-thaw DoE conducted in this thesis. These freezers bracket the commercial scale 
freezer which has a set-point of -30 ºC.  
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Table 5-1: Experimental overview for determination of freezing kinetics and thermal 
conductivity for different freezers with different temperature set points 
Bottle size (L) / 
fill (kg) 
Number of bottles to be frozen per freezer 
-20 °C  
(Lab Scale) 
-30 °C  
(Manufacturing Scale) 
-80 °C  
(Lab Scale) 
0.125 / 0.0875 
1 1 1 
9 9 9 
1 / 0.7 
1 1 1 
2 6 6 
2 / 1.4 
1 n/a n/a 
2 4 4 
4 n/a n/a 
5 / 3.5 
n/a 1 1 
n/a 4 4 
 
Power is calculated as Joules per second. Therefore, the power of each freezer can be 
determined by multiplying the mass of ice frozen by the latent heat of fusion for ice 
and dividing by the freezing plateau time, as measured from the temperature profiles. 
Plotting the power versus observed freezer temperature allows an empirical correlation 
of the freezing time for each freezer that is equivalent to that determined by the Plank 
equation. The heat transfer coefficient (h) is calculated empirically, as the surface area, 
freezer temperature and power are all known or calculated values. This allows 
prediction of freezing time and temperature for any size and quantity of product using 
relatively simple algebraic equations. 
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6.0 CONCLUSIONS 
This research project was conceived to perform a high-level experimental assessment 
of the freeze and thaw process for Protein Y FDS in polycarbonate bottles at a reduced 
scale (lower than commercial volumes) in order to evaluate the effect of freeze/thaw 
parameters on Protein Y aggregation and tertiary structure in a formulated therapeutic 
protein solution. The work was envisaged to assess the scalability of these experiments 
to the respective full-scale commercial process. 
Analytical methods for characterisation of Protein Y were developed to detect changes 
in aggregation and tertiary structure of the protein. The methods were then utilised as 
responses, along with analysis of temperature/time profiles in a DoE study to assess 
the main process factors affecting these responses. The DoE demonstrated that the 
factors studied can have a statistically significant impact on temperature profile and 
consequently rate of heat transfer. The experiments showed that slower rates of 
freezing induced by co-loading of bottles, result in changes to the tertiary structure and 
subsequently in subtle aggregation changes as determined by DLS. Similarly, slower 
thaw rates were also shown to have more impact on changes in tertiary structure and 
aggregation as measured by DLS.   
With respect to scalability of the experiments, despite the shorter freeze and thaw 
times, which would be expected with a smaller volume of FDS, the DLS data supports 
that levels of aggregation are equivalent to the bulk control FDS material over time. 
Also, while fluorescence, near-UV CD and 2nd derivative UV did show slight changes 
in protein tertiary structure. Determination of SA:V ratios for laboratory and 
commercial scale respectively, and the use of the differential as a scaling factor 
resulted in reasonable prediction of expected freeze and thaw time for the commercial 
scale using empirical models established using DoE results.  
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